TEMOZOLOMIDE- temozolomide capsule Lannett Company, Inc.

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use temozolomide safely and effectively. See full prescribing information for temozolomide. TEMOZOLOMIDE Capsules for oral use Initial U.S. Approval: 1999
INDICATIONS AND USAGE
Temozolomide is an alkylating drug indicated for the treatment of adult patients with:
• Newly diagnosed glioblastoma multiforme (GBM) concomitantly with radiotherapy and then as maintenance treatment.
(1.1)
• Refractory anaplastic astrocytoma patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine. (1.2)
DOSAGE AND ADMINISTRATION
• Newly Diagnosed GBM: 75 mg/m ² for 42 days concomitant with focal radiotherapy followed by initial maintenance dose of 150 mg/m ² once daily for Days 1-5 of a 28-day cycle of temozolomide for 6 cycles. (2.1)
• Refractory Anaplastic Astrocytoma: Initial dose 150 mg/m ² once daily for 5 consecutive days per 28-day treatment cycle. (2.1)
DOSAGE FORMS AND STRENGTHS
• 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg capsules. (3)
CONTRAINDICATIONS
• Known hypersensitivity to any temozolomide component or to dacarbazine (DTIC). (4.1)
WARNINGS AND PRECAUTIONS
Myelosuppression - monitor Absolute Neutrophil Count (ANC) and platelet count prior to dosing and throughout
treatment. Geriatric patients and women have a higher risk of developing myelosuppression. (5.1)
 Cases of myelodysplastic syndrome and secondary malignancies, including myeloid leukemia, have been observed. (5.2)
 Pneumocystis pneumonia (PCP) – PCP prophylaxis required for all patients receiving concomitant temozolomide and
radiotherapy for the 42-day regimen for the treatment of newly diagnosed glioblastoma multiforme. (5.3)
 All patients, particularly those receiving steroids, should be observed closely for the development of lymphopenia and PCP. (5.4)
• Complete blood counts should be obtained throughout the treatment course as specified. (5.4)
• Hepatotoxicity – fatal and severe hepatotoxicity have been reported. Perform liver function tests at baseline, midway through the first cycle, prior to each subsequent cycle, and approximately two to four weeks after the last dose of temozolomide. (5.5)
 Fetal harm can occur when administered to a pregnant woman. Women should be advised to avoid becoming pregnant when receiving temozolomide. (5.6)
• As bioequivalence has been established only when given over 90 minutes, infusion over a shorter or longer period of time may result in suboptimal dosing; the possibility of an increase in infusion-related adverse reactions cannot be ruled out. (5.7)
ADVERSE REACTIONS
• The most common adverse reactions (greater than or equal to 10% incidence) are: alopecia, fatigue, nausea, vomiting, headache, constipation, anorexia, convulsions, rash, hemiparesis, diarrhea, asthenia, fever, dizziness, coordination abnormal, viral infection, amnesia, and insomnia. (6.1)
 The most common Grade 3 to 4 hematologic laboratory abnormalities (greater than or equal to 10% incidence) that have developed during treatment with temozolomide are: lymphopenia, thrombocytopenia, neutropenia, and leukopenia. (6.1)
 Allergic reactions have also been reported. (6)
To report SUSPECTED ADVERSE REACTIONS, contact Lannett Company, Inc. at 1-800-325-9994 or FDA at 1- 800-FDA-1088 or www.fda.gov/medwatch.
DRUG INTERACTIONS

• Valproic acid: decreases oral clearance of temozolomide. (7.1)

------USE IN SPECIFIC POPULATIONS ------

- Nursing mothers: Not recommended. (8.3)
- Pediatric use: No established use. (8.4)
- Hepatic/Renal Impairment: Caution should be exercised when temozolomide is administered to patients with severe renal or hepatic impairment. (8.6, 8.7)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 12/2015

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

- 1.1 Newly Diagnosed Glioblastoma Multiforme
- 1.2 Refractory Anaplastic Astrocytoma

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dosing and Dose Modification Guidelines

2.2 Preparation and Administration

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

4.1 Hypersensitivity

5 WARNINGS AND PRECAUTIONS

- 5.1 Myelosuppression
- 5.2 Myelodysplastic Syndrome
- 5.3 Pneumocystis Pneumonia
- 5.4 Laboratory Tests
- 5.5 Hepatotoxicity
- 5.6 Use in Pregnancy
- 5.7 Infusion Time

6 ADVERSE REACTIONS

- 6.1 Clinical Trials Experience
- 6.2 Postmarketing Experience

7 DRUG INTERACTIONS

7.1 Valproic Acid

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.3 Nursing Mothers
- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Renal Impairment
- 8.7 Hepatic Impairment
- **10 OVERDOSAGE**

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
- 13.2 Animal Toxicology and/or Pharmacology

14 CLINICAL STUDIES

14.1 Newly Diagnosed Glioblastoma Multiforme

14.2 Refractory Anaplastic Astrocytoma **15 REFERENCES 16 HOW SUPPLIED/STORAGE AND HANDLING** 16.1 Safe Handling and Disposal 16.2 How Supplied 16.3 Storage **17 PATIENT COUNSELING INFORMATION** 17.1 Information for the Patient IMPORTANT DISPENSING INFORMATION

Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

1.1 Newly Diagnosed Glioblastoma Multiforme

Temozolomide is indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment.

1.2 Refractory Anaplastic Astrocytoma

Temozolomide is indicated for the treatment of adult patients with refractory anaplastic astrocytoma, i.e., patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine.

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dosing and Dose Modification Guidelines

The recommended dose for temozolomide as an intravenous infusion over 90 minutes is the same as the dose for the oral capsule formulation. Bioequivalence has been established only when temozolomide for Injection was given over 90 minutes [see Clinical Pharmacology (12.3)]. Dosage of temozolomide must be adjusted according to nadir neutrophil and platelet counts in the previous cycle and the neutrophil and platelet counts at the time of initiating the next cycle. For temozolomide dosage calculations based on body surface area (BSA) see **Table 5**. For suggested capsule combinations on a daily dose see **Table 6**.

Patients with Newly Diagnosed High Grade Glioma: Concomitant Phase: Temozolomide is administered at 75 mg/m² daily for 42 days concomitant with focal radiotherapy (60 Gy administered in 30 fractions) followed by maintenance temozolomide for 6 cycles. Focal RT includes the tumor bed or resection site with a 2- to 3-cm margin. No dose reductions are recommended during the concomitant phase; however, dose interruptions or discontinuation may occur based on toxicity. The temozolomide dose should be continued throughout the 42-day concomitant period up to 49 days if all of the following conditions are met: absolute neutrophil count greater than or equal to $1.5 \ge 10^9$ /L, platelet count greater than or equal to 100 x 10⁹/L, common toxicity criteria (CTC) nonhematological toxicity less than or equal to Grade 1 (except for alopecia, nausea, and vomiting). During treatment a complete blood count should be obtained weekly. Temozolomide dosing should be interrupted or discontinued during concomitant phase according to the hematological and nonhematological toxicity criteria as noted in **Table 1**. *Pneumocystis* pneumonia (PCP) prophylaxis is required during the concomitant administration of temozolomide and radiotherapy, and should be continued in patients who develop lymphocytopenia until recovery from lymphocytopenia (CTC Grade less than or equal to 1).

TABLE 1: Temozolomide Dosing Interruption orDiscontinuation During ConcomitantRadiotherapy and Temozolomide

Toxicity	TMZ Interruption*	TMZ Discontinuation
Absolute Neutrophil Count	greater than or equal to 0.5 and less than 1.5 x 10 ⁹ /L	less than 0.5 x 10 ⁹ /L
Platelet Count	greater than or equal to 10 and less than 100 x 10 ⁹ /L	less than 10 x 10 ⁹ /L
CTC Nonhematological Toxicity (except for alopecia, nausea, vomiting)	CTC Grade 2	CTC Grade 3 or 4

*Treatment with concomitant TMZ could be continued when all of the following conditions were met: absolute neutrophil count greater than or equal to 1.5×10^9 /L; platelet count greater than or equal to 100 x 10^9 /L; CTC nonhematological toxicity less than or equal to Grade 1 (except for alopecia, nausea, vomiting).

TMZ=temozolomide; CTC=Common Toxicity Criteria.

Maintenance Phase:

Cycle 1: Four weeks after completing the temozolomide+RT phase, temozolomide is administered for an additional 6 cycles of maintenance treatment. Dosage in Cycle 1 (maintenance) is 150 mg/m² once daily for 5 days followed by 23 days without treatment.

Cycles 2-6: At the start of Cycle 2, the dose can be escalated to 200 mg/m², if the CTC nonhematologic toxicity for Cycle 1 is Grade less than or equal to 2 (except for alopecia, nausea, and vomiting), absolute neutrophil count (ANC) is greater than or equal to 1.5×10^{9} /L, and the platelet count is greater than or equal to 100×10^{9} /L. The dose remains at 200 mg/m² per day for the first 5 days of each subsequent cycle except if toxicity occurs. If the dose was not escalated at Cycle 2, escalation should not be done in subsequent cycles.

Dose Reduction or Discontinuation During Maintenance: Dose reductions during the maintenance phase should be applied according to **Tables 2** and **3**.

During treatment, a complete blood count should be obtained on Day 22 (21 days after the first dose of temozolomide) or within 48 hours of that day, and weekly until the ANC is above 1.5×10^9 /L (1500/µL) and the platelet count exceeds 100×10^9 /L (100,000/µL). The next cycle of temozolomide should not be started until the ANC and platelet count exceed these levels. Dose reductions during the next cycle should be based on the lowest blood counts and worst nonhematologic toxicity during the previous cycle. Dose reductions or discontinuations during the maintenance phase should be applied according to **Tables 2** and **3**.

TABLE 2: Temozolomide Dose Levels for

Dose Level	Dose (mg/m ² /day)	Remarks
		Reduction
-1	100	for prior
		toxicity
		Dose
0	150	during
		Cycle 1
		Dose
		during
		Cycles 2-
1	200	6 in
		absence
		of
		toxicity

Maintenance Treatment

TABLE 3: Temozolomide Dose Reduction orDiscontinuation During Maintenance Treatment

Toxicity	Reduce TMZ by 1 Dose Level*	Discontinue TMZ
Absolute Neutrophil Count	less than 1.0 x 10 ⁹ /L	See footnote [†]
Platelet Count	less than 50 x 10 ⁹ /L	See footnote [†]
CTC Nonhematological Toxicity (except for alopecia, nausea, vomiting)	CTC Grade 3	CTC Grade 4 [†]

*TMZ dose levels are listed in **Table 2**.

[†]TMZ is to be discontinued if dose reduction to less than 100 mg/m² is required or if the same Grade 3 nonhematological toxicity (except for alopecia, nausea, vomiting) recurs after dose reduction. TMZ=temozolomide; CTC=Common Toxicity Criteria.

Patients with Refractory Anaplastic Astrocytoma: For adults the initial dose is 150 mg/m² once daily for 5 consecutive days per 28-day treatment cycle. For adult patients, if both the nadir and day of dosing (Day 29, Day 1 of next cycle) ANC are greater than or equal to 1.5×10^9 /L ($1500/\mu$ L) and both the nadir and Day 29, Day 1 of next cycle platelet counts are greater than or equal to 100×10^9 /L ($100,000/\mu$ L), the temozolomide dose may be increased to 200 mg/m²/day for 5 consecutive days per 28-day treatment cycle. During treatment, a complete blood count should be obtained on Day 22 (21 days after the first dose) or within 48 hours of that day, and weekly until the ANC is above 1.5×10^9 /L ($1500/\mu$ L) and the platelet count exceeds 100×10^9 /L ($100,000/\mu$ L). The next cycle of temozolomide should not be started until the ANC and platelet count exceed these levels. If the ANC falls to less than 1 x 10^9 /L ($1000/\mu$ L) or the platelet count is less than 50 x 10^9 /L ($50,000/\mu$ L) during any cycle, the next cycle should be reduced by 50 mg/m², but not below 100 mg/m², the lowest recommended dose (see **T able 4**). Temozolomide therapy can be continued until disease progression. In the clinical trial, treatment could be continued for a maximum of 2 years, but the optimum duration of therapy is not known.

TABLE 4: Dosing Modification Table

150 mg/m ² /d x 5d (Starting Dose) or 200 mg/m ² /d x 5d		Measure Day 22 ANC and platelets
		355)
*		
Measure ANC	and platelets on D	Day 29 (Day 1 of
	next cycle)	
	Ļ	
Based on lowes	st counts at either	Day 22 or Day 29
Ļ	t.	Ļ
ANC less than 1000/µL or platelets less than 50,000/µL	ANC 1000/μL – 1500/μL or platelets 50,000/μL – 100,000/μL	ANC greater than 1500/µL and platelets greater than 100,000/µL
Ļ	Ļ	Ļ
Postpone therapy until ANC greater than 1500/µL and platelets greater than 100,000/µL; reduce dose by 50 mg/m ² /d for subsequent cycle	Postpone therapy until ANC greater than 1500/µL and platelets greater than 100,000/µL; maintain initial dose	Increase dose to, or maintain dose at, 200 mg/m ² /d x 5d for subsequent cycle

TABLE 5: Daily Dose Calculations by BodySurface Area (BSA)

Total BSA (m ²)	75 mg/m ² (mg daily)	150 mg/m ² (mg daily)	200 mg/m ² (mg daily)
1	75	150	200
1.1	82.5	165	220
1.2	90	180	240
1.3	97.5	195	260
1.4	105	210	280

1.5	112.5	225	300
1.6	120	240	320
1.7	127.5	255	340
1.8	135	270	360
1.9	142.5	285	380
2	150	300	400
2.1	157.5	315	420
2.2	165	330	440
2.3	172.5	345	460
2.4	180	360	480
2.5	187.5	375	500

TABLE 6: Suggested Capsule CombinationsBased on Daily Dose in Adults

Num	Number of Daily Capsules by Strength (mg)								
Total Daily Dose	250 mg	180 mg	140 mg	100 mg	20 mg	5 mg			
(mg)									
75	0	0	0	0	3	3			
82.5	0	0	0	0	4	0			
90	0	0	0	0	4	2			
97.5	0	0	0	1	0	0			
105	0	0	0	1	0	1			
112.5	0	0	0	1	0	2			
120	0	0	0	1	1	0			
127.5	0	0	0	1	1	1			
135	0	0	0	1	1	3			
142.5	0	0	1	0	0	0			
150	0	0	1	0	0	2			
157.5	0	0	1	0	1	0			
165	0	0	1	0	1	1			
172.5	0	0	1	0	1	2			
180	0	1	0	0	0	0			
187.5	0	1	0	0	0	1			
195	0	1	0	0	0	3			
200	0	1	0	0	1	0			
210	0	0	0	2	0	2			
220	0	0	0	2	1	0			
225	0	0	0	2	1	1			
240	0	0	1	1	0	0			
255	1	0	0	0	0	1			
260	1	0	0	0	0	2			
270	1	0	0	0	1	0			
280	0	0	2	0	0	0			
285	0	0	2	0	0	1			

300	0	0	0	3	0	0
315	0	0	0	3	0	3
320	0	1	1	0	0	0
330	0	1	1	0	0	2
340	0	1	1	0	1	0
345	0	1	1	0	1	1
360	0	2	0	0	0	0
375	0	2	0	0	0	3
380	0	1	0	2	0	0
400	0	0	0	4	0	0
420	0	0	3	0	0	0
440	0	0	3	0	1	0
460	0	2	0	1	0	0
480	0	1	0	3	0	0
500	2	0	0	0	0	0

2.2 Preparation and Adminis tration

Temozolomide Capsules: In clinical trials, temozolomide was administered under both fasting and nonfasting conditions; however, absorption is affected by food [see Clinical Pharmacology (12.3)], and consistency of administration with respect to food is recommended. There are no dietary restrictions with temozolomide. To reduce nausea and vomiting, temozolomide should be taken on an empty stomach. Bedtime administration may be advised. Antiemetic therapy may be administered prior to and/or following administration of temozolomide.

Temozolomide capsules should not be opened or chewed. They should be swallowed whole with a glass of water. If capsules are accidentally opened or damaged, precautions should be taken to avoid inhalation or contact with the skin or mucous membranes [see How Supplied/Storage and Handling (16.1)].

3 DOSAGE FORMS AND STRENGTHS

- Temozolomide Capsules for oral administration
 - 5-mg capsules have an olive opaque cap and white opaque body. They are imprinted with "Lannett" on the cap and "1777" over "5 mg" on the body.
 - 20-mg capsules have an orange opaque cap and white opaque body. They are imprinted with "Lannett" on the cap and "1778" over "20 mg" on the body.
 - 100-mg capsules have a flesh opaque cap and white opaque body. They are imprinted with "Lannett" on the cap and "1779" over "100 mg" on the body.
 - 140-mg capsules have an aqua blue opaque cap and white opaque body. They are imprinted with "Lannett" on the cap and "1780" over "140 mg" on the body.
 - 180-mg capsules have a Swedish orange opaque cap and white opaque body. They are imprinted with "Lannett" on the cap and "1781" over "180 mg" on the body.
 - 250-mg capsules have a white opaque cap and white opaque body. They are imprinted with "Lannett" on the cap and "1782" over "250 mg" on the body.

4 CONTRAINDICATIONS

4.1 Hypersensitivity

Temozolomide is contraindicated in patients who have a history of hypersensitivity reaction (such as

urticaria, allergic reaction including anaphylaxis, toxic epidermal necrolysis, and Stevens-Johnson syndrome) to any of its components. Temozolomide is also contraindicated in patients who have a history of hypersensitivity to dacarbazine (DTIC), since both drugs are metabolized to 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide (MTIC).

5 WARNINGS AND PRECAUTIONS

5.1 Myelosuppression

Patients treated with temozolomide may experience myelosuppression, including prolonged pancytopenia, which may result in aplastic anemia, which in some cases has resulted in a fatal outcome. In some cases, exposure to concomitant medications associated with aplastic anemia, including carbamazepine, phenytoin, and sulfamethoxazole/trimethoprim, complicates assessment. Prior to dosing, patients must have an absolute neutrophil count (ANC) greater than or equal to 1.5×10^9 /L and a platelet count greater than or equal to 100×10^9 /L. A complete blood count should be obtained on Day 22 (21 days after the first dose) or within 48 hours of that day, and weekly until the ANC is above 1.5×10^9 /L and platelet count exceeds 100×10^9 /L. Geriatric patients and women have been shown in clinical trials to have a higher risk of developing myelosuppression.

5.2 Myelodys plastic Syndrome

Cases of myelodysplastic syndrome and secondary malignancies, including myeloid leukemia, have been observed.

5.3 Pneumocystis Pneumonia

For treatment of newly diagnosed glioblastoma multiforme: Prophylaxis against *Pneumocystis* pneumonia (PCP) is required for all patients receiving concomitant temozolomide and radiotherapy for the 42-day regimen.

There may be a higher occurrence of PCP when temozolomide is administered during a longer dosing regimen. However, all patients receiving temozolomide, particularly patients receiving steroids, should be observed closely for the development of PCP regardless of the regimen.

5.4 Laboratory Tests

For the concomitant treatment phase with RT, a complete blood count should be obtained prior to initiation of treatment and weekly during treatment.

For the 28-day treatment cycles, a complete blood count should be obtained prior to treatment on Day 1 and on Day 22 (21 days after the first dose) of each cycle. Blood counts should be performed weekly until recovery if the ANC falls below 1.5×10^9 /L and the platelet count falls below 100×10^9 /L [see *Recommended Dosing and Dose Modification Guidelines (2.1)*].

5.5 Hepatotoxicity

Fatal and severe hepatotoxicity have been reported in patients receiving temozolomide. Perform liver function tests at baseline, midway through the first cycle, prior to each subsequent cycle, and approximately two to four weeks after the last dose of temozolomide.

5.6 Use in Pregnancy

Temozolomide can cause fetal harm when administered to a pregnant woman. Administration of temozolomide to rats and rabbits during organogenesis at 0.38 and 0.75 times the maximum recommended human dose (75 and 150 mg/m²), respectively, caused numerous fetal malformations of the external organs, soft tissues, and skeleton in both species [see Use in Specific Populations (8.1)].

5.7 Infusion Time

As bioequivalence has been established only when temozolomide for Injection was given over 90 minutes, infusion over a shorter or longer period of time may result in suboptimal dosing. Additionally, the possibility of an increase in infusion-related adverse reactions cannot be ruled out.

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Newly Diagnosed Glioblastoma Multiforme: During the concomitant phase

(temozolomide+radiotherapy), adverse reactions including thrombocytopenia, nausea, vomiting, anorexia, and constipation were more frequent in the temozolomide+RT arm. The incidence of other adverse reactions was comparable in the two arms. The most common adverse reactions across the cumulative temozolomide experience were alopecia, nausea, vomiting, anorexia, headache, and constipation (see **Table 7**). Forty-nine percent (49%) of patients treated with temozolomide reported one or more severe or life-threatening reactions, most commonly fatigue (13%), convulsions (6%), headache (5%), and thrombocytopenia (5%). Overall, the pattern of reactions during the maintenance phase was consistent with the known safety profile of temozolomide.

		· `						·				
	Concomitant Phase RT Alone (n=285)			Concomitant Phase RT+TMZ (n=288)*				Maintenance Phase TMZ (n=224)				
	A		Grad	le ≥3	A	All		Grade ≥3		All		de ≥3
Subjects Reporting any Adverse Reaction	258	(91)	74	(26)	266	(92)	80	(28)	206	(92)	82	(37)
Body as a Whole — General Disorders												
Anorexia	25	(9)	1	(<1)	56	(19)	2	(1)	61	(27)	3	(1)
Dizziness	10	(4)	0		12	(4)	2	(1)	12	(5)	0	
Fatigue	139	(49)	15	(5)	156	(54)	19	(7)	137	(61)	20	(9)
Headache	49	(17)	11	(4)	56	(19)	5	(2)	51	(23)	9	(4)
Weakness	9	(3)	3	(1)	10	(3)	5	(2)	16	(7)	4	(2)
Central and Peripheral												
Nervous System Disorders												
Confusion	12	(4)	6	(2)	11	(4)	4	(1)	12	(5)	4	(2)
Convulsions	20	(7)	9	(3)	17	(6)	10	(3)	25	(11)	7	(3)
Memory Impairment	12	(4)	1	(<1)	8	(3)	1	(<1)	16	(7)	2	(1)
Disorders of the Eye												
Vision Blurred	25	(9)	4	(1)	26	(9)	2	(1)	17	(8)	0	
Disorders of the Immune												
System												
Allergic Reaction	7	(2)	1	(<1)	13	(5)	0		6	(3)	0	
Gas trointes tinal Sys tem Dis orders												
Abdominal Pain	2	(1)	0		7	(2)	1	(<1)	11	(5)	1	(<1)
Constipation	18	(6)	0		53	(18)	3	(1)	49	(22)	0	

TABLE 7: Number (%) of Patients with Adverse Reactions: All and Severe/LifeThreatening (Incidence of 5% or Greater)

Diarrhea	9	(3)	0		18	(6)	0		23	(10)	2	(1)
Nausea	45	(16)	1	(<1)	105	(36)	2	(1)	110	(49)	3	(1)
Stomatitis	14	(5)	1	(<1)	19	(7)	0		20	(9)	3	(1)
Vomiting	16	(6)	1	(<1)	57	(20)	1	(<1)	66	(29)	4	(2)
Injury and Poisoning												
Radiation Injury NOS	11	(4)	1	(<1)	20	(7)	0		5	(2)	0	
Mus culos keletal Sys tem												
Disorders												
Arthralgia	2	(1)	0		7	(2)	1	(<1)	14	(6)	0	
Platelet, Bleeding and												
Clotting Disorders												
Thrombocytopenia	3	(1)	0		11	(4)	8	(3)	19	(8)	8	(4)
Psychiatric Disorders												
Insomnia	9	(3)	1	(<1)	14	(5)	0		9	(4)	0	
Respiratory System												
Disorders												
Coughing	3	(1)	0		15	(5)	2	(1)	19	(8)	1	(<1)
Dyspnea	9	(3)	4	(1)	11	(4)	5	(2)	12	(5)	1	(<1)
Skin and Subcutaneous												
Tissue Disorders												
Alopecia	179	(63)	0		199	(69)	0		124	(55)	0	
Dry Skin	6	(2)	0		7	(2)	0		11	(5)	1	(<1)
Erythema	15	(5)	0		14	(5)	0		2	(1)	0	
Pruritus	4	(1)	0		11	(4)	0		11	(5)	0	
Rash	42	(15)	0		56	(19)	3	(1)	29	(13)	3	(1)
Special Senses, Other												
Disorders												
Taste Perversion	6	(2)	0		18	(6)	0		11	(5)	0	
	Ŭ	(-)	v		10		0		* *		0	1

*One patient who was randomized to RT only arm received RT+temozolomide.

RT+TMZ=radiotherapy plus temozolomide; NOS=not otherwise specified.

Note: Grade 5 (fatal) adverse reactions are included in the Grade \geq 3 column.

Myelosuppression (neutropenia and thrombocytopenia), which is a known dose-limiting toxicity for most cytotoxic agents, including temozolomide, was observed. When laboratory abnormalities and adverse reactions were combined, Grade 3 or Grade 4 neutrophil abnormalities including neutropenic reactions were observed in 8% of the patients, and Grade 3 or Grade 4 platelet abnormalities, including thrombocytopenic reactions, were observed in 14% of the patients treated with temozolomide.

Refractory Anaplastic Astrocytoma: Tables 8 and **9** show the incidence of adverse reactions in the 158 patients in the anaplastic astrocytoma study for whom data are available. In the absence of a control group, it is not clear in many cases whether these reactions should be attributed to temozolomide or the patients' underlying conditions, but nausea, vomiting, fatigue, and hematologic effects appear to be clearly drug-related. The most frequently occurring adverse reactions were nausea, vomiting, headache, and fatigue. The adverse reactions were usually NCI Common Toxicity Criteria (CTC) Grade 1 or 2 (mild to moderate in severity) and were self-limiting, with nausea and vomiting readily controlled with antiemetics. The incidence of severe nausea and vomiting (CTC Grade 3 or 4) was 10% and 6%, respectively. Myelosuppression (thrombocytopenia and neutropenia) was the dose-limiting adverse reaction. It usually occurred within the first few cycles of therapy and was not cumulative.

Myelosuppression occurred late in the treatment cycle and returned to normal, on average, within 14 days of nadir counts. The median nadirs occurred at 26 days for platelets (range: 21-40 days) and 28 days for neutrophils (range: 1-44 days). Only 14% (22/158) of patients had a neutrophil nadir and 20%

(32/158) of patients had a platelet nadir, which may have delayed the start of the next cycle. Less than 10% of patients required hospitalization, blood transfusion, or discontinuation of therapy due to myelosuppression.

In clinical trial experience with 110 to 111 women and 169 to 174 men (depending on measurements), there were higher rates of Grade 4 neutropenia (ANC less than 500 cells/ μ L) and thrombocytopenia (less than 20,000 cells/ μ L) in women than men in the first cycle of therapy (12% vs. 5% and 9% vs. 3%, respectively).

In the entire safety database for which hematologic data exist (N=932), 7% (4/61) and 9.5% (6/63) of patients over age 70 experienced Grade 4 neutropenia or thrombocytopenia in the first cycle, respectively. For patients less than or equal to age 70, 7% (62/871) and 5.5% (48/879) experienced Grade 4 neutropenia or thrombocytopenia in the first cycle, respectively. Pancytopenia, leukopenia, and anemia have also been reported.

	No. (%) of Temozolomide Patien (N=158)					
	All Reactions	Grade 3/4				
Any Adverse Reaction	153 (97)	79 (50)				
Body as a Whole						
Headache	65 (41)	10 (6)				
Fatigue	54 (34)	7 (4)				
Asthenia	20 (13)	9 (6)				
Fever	21 (13)	3 (2)				
Back pain	12 (8)	4 (3)				
Cardiovas cular						
Edema peripheral	17 (11)	1 (1)				
Central and Peripheral						
Nervous System						
Convulsions	36 (23)	8 (5)				
Hemiparesis	29 (18)	10 (6)				
Dizziness	19 (12)	1 (1)				
Coordination abnormal	17 (11)	2 (1)				
Amnesia	16 (10)	6 (4)				
Insomnia	16 (10)	0				
Paresthesia	15 (9)	1 (1)				
Somnolence	15 (9)	5 (3)				
Paresis	13 (8)	4 (3)				
Urinary incontinence	13 (8)	3 (2)				
Ataxia	12 (8)	3 (2)				
Dysphasia	11 (7)	1 (1)				
Convulsions local	9 (6)	0				
Gait abnormal	9 (6)	1 (1)				
Confusion	8 (5)	0				
Endocrine						
Adrenal hypercorticism	13 (8)	0				
Gas trointes tinal Sys tem						

TABLE 8: Adverse Reactions in the Anaplastic Astrocytoma Trial in Adults (≥5%)

Nausea	84 (53)	16 (10)
Vomiting	66 (42)	10 (6)
Constipation	52 (33)	1 (1)
Diarrhea	25 (16)	3 (2)
Abdominal pain	14 (9)	2 (1)
Anorexia	14 (9)	1(1)
Metabolic		
Weight increase	8 (5)	0
Musculoskeletal		
System		
Myalgia	8 (5)	
Psychiatric Disorders		
Anxiety	11 (7)	1 (1)
Depression	10 (6)	0
Reproductive		
Disorders		
Breast pain, female	4 (6)	
Resistance Mechanism		
Disorders		
Infection viral	17 (11)	0
Respiratory System		
Upper respiratory tract infection	13 (8)	0
Pharyngitis	12 (8)	0
Sinusitis	10 (6)	0
Coughing	8 (5)	0
Skin and Appendages		
Rash	13 (8)	0
Pruritus	12 (8)	2 (1)
Urinary System		
Urinary tract infection	12 (8)	0
Micturition increased		0
frequency	9 (6)	0
Vision		
Diplopia	8 (5)	0
Vision abnormal*	8 (5)	

*Blurred vision; visual deficit; vision changes; vision troubles

TABLE 9: Adverse Hematologic Effects (Grade3 to 4) in the Anaplastic Astrocytoma Trial inAdults

	Temozolomide*
Hemoglobin	7/158 (4%)
Lymphopenia	83/152 (55%)
Neutrophils	20/142 (14%)
Platelets	29/156 (19%)
WBC	18/158 (11%)

*Change from Grade 0 to 2 at baseline to Grade 3 or 4 during treatment.

Temozolomide for injection delivers equivalent temozolomide dose and exposure to both temozolomide and 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide (MTIC) as the corresponding temozolomide capsules. Adverse reactions probably related to treatment that were reported from the 2 studies with the intravenous formulation (n=35) that were not reported in studies using the temozolomide capsules were: pain, irritation, pruritus, warmth, swelling, and erythema at infusion site as well as the following adverse reactions: petechiae and hematoma.

6.2 Postmarketing Experience

The following adverse reactions have been identified during postapproval use of temozolomide. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to the drug exposure.

Dermatologic disorders: Toxic epidermal necrolysis and Stevens-Johnson syndrome

<u>Immune system disorders</u>: Allergic reactions, including anaphylaxis. Erythema multiforme, which resolved after discontinuation of temozolomide and, in some cases, recurred upon rechallenge.

<u>Hematopoietic disorders</u>: Prolonged pancytopenia, which may result in aplastic anemia and fatal outcomes [*see Warnings and Precautions* (5.1)].

<u>Hepatobiliary disorders</u>: Fatal and severe hepatotoxicity, elevation of liver enzymes, hyperbilirubinemia, cholestasis, and hepatitis *[see Warnings and Precautions (5.5)]*.

<u>Infections and infestations</u>: Opportunistic infections including *Pneumocystis* pneumonia (PCP) [*see Warnings and Precautions (5.3)*], primary and reactivated cytomegalovirus (CMV), and reactivation of hepatitis B infections including some cases with fatal outcomes.

<u>Pulmonary disorders</u>: Interstitial pneumonitis, pneumonitis, alveolitis, and pulmonary fibrosis.

Endocrine disorders: Diabetes insipidus

7 DRUG INTERACTIONS

7.1 Valproic Acid

Administration of valproic acid decreases oral clearance of temozolomide by about 5%. The clinical implication of this effect is not known [see Clinical Pharmacology (12.3)].

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category D. See Warnings and Precautions section.

Temozolomide can cause fetal harm when administered to a pregnant woman. Five consecutive days of oral temozolomide administration of 0.38 and 0.75 times the highest recommended human dose (75 and 150 mg/m²) in rats and rabbits, respectively, during the period of organogenesis caused numerous malformations of the external and internal soft tissues and skeleton in both species. Doses equivalent to 0.75 times the highest recommended human dose (150 mg/m²) caused embryolethality in rats and rabbits as indicated by increased resorptions. There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus. Women of childbearing potential should be advised to avoid becoming pregnant during therapy with temozolomide.

8.3 Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants and tumorigenicity

shown for temozolomide in animal studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of temozolomide to the mother.

8.4 Pediatric Use

Safety and effectiveness in pediatric patients have not been established. Temozolomide capsules have been studied in 2 open-label studies in pediatric patients (aged 3-18 years) at a dose of 160 to 200 mg/m² daily for 5 days every 28 days. In one trial, 29 patients with recurrent brain stem glioma and 34 patients with recurrent high grade astrocytoma were enrolled. All patients had recurrence following surgery and radiation therapy, while 31% also had disease progression following chemotherapy. In a second study conducted by the Children's Oncology Group (COG), 122 patients were enrolled, including patients with medulloblastoma/PNET (29), high grade astrocytoma (23), low grade astrocytoma (22), brain stem glioma (16), ependymoma (14), other CNS tumors (9), and non-CNS tumors (9). The temozolomide toxicity profile in pediatric patients is similar to adults. **Table 10** shows the adverse reactions in 122 children in the COG study.

TABLE 10: Adverse Reactions Reported in the Pediatric Cooperative Group Trial (≥10%)

_				
No. (%) of Temozolomide Capsules Patients				
			(N=]	[22)*
			All	
	Grade 3/4			
Reactions				
107 (88)	69 (57)			
- ()				
22 (18)	13 (11)			
22 (10)	15(11)			
56 (46)	5 (4)			
62 (51)	4 (3)			
71 (58)	31 (25)			
62 (51)	7 (6)			
71 (58)	21 (17)			
73 (60)	48 (39)			
62 (51)	24 (20)			
	Temoz Capsules (N=1 All Reactions 107 (88) 22 (18) 22 (18) 22 (18) 56 (46) 62 (51) 71 (58) 73 (60)			

*These various tumors included the following: PNET-medulloblastoma, glioblastoma, low grade astrocytoma, brain stem tumor, ependymoma, mixed glioma, oligodendroglioma, neuroblastoma, Ewing's sarcoma, pineoblastoma, alveolar soft part sarcoma, neurofibrosarcoma, optic glioma, and osteosarcoma.

8.5 Geriatric Use

Clinical studies of temozolomide did not include sufficient numbers of subjects aged 65 and over to determine whether they responded differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

In the anaplastic astrocytoma study population, patients 70 years of age or older had a higher incidence of Grade 4 neutropenia and Grade 4 thrombocytopenia (2/8; 25%, *P*=0.31 and 2/10; 20%, *P*=0.09, respectively) in the first cycle of therapy than patients under 70 years of age [see Warnings and Precautions (5.1) and Adverse Reactions (6.1)].

In newly diagnosed patients with glioblastoma multiforme, the adverse reaction profile was similar in younger patients (less than 65 years) vs. older (greater than or equal to 65 years).

8.6 Renal Impairment

Caution should be exercised when temozolomide is administered to patients with severe renal impairment [*see Clinical Pharmacology* (12.3)].

8.7 Hepatic Impairment


Caution should be exercised when temozolomide is administered to patients with severe hepatic impairment [*see Clinical Pharmacology* (12.3)].

10 OVERDOSAGE

Doses of 500, 750, 1000, and 1250 mg/m² (total dose per cycle over 5 days) have been evaluated clinically in patients. Dose-limiting toxicity was hematologic and was reported with any dose but is expected to be more severe at higher doses. An overdose of 2000 mg per day for 5 days was taken by one patient and the adverse reactions reported were pancytopenia, pyrexia, multi-organ failure, and death. There are reports of patients who have taken more than 5 days of treatment (up to 64 days), with adverse reactions reported including bone marrow suppression, which in some cases was severe and prolonged, and infections and resulted in death. In the event of an overdose, hematologic evaluation is needed. Supportive measures should be provided as necessary.

11 DESCRIPTION

Temozolomide capsules contain temozolomide, an imidazotetrazine derivative. The chemical name of temozolomide is 3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-*as*-tetrazine-8-carboxamide. The structural formula is:



The material is a white to light tan/light pink powder with a molecular formula of $C_6H_6N_6O_2$ and a molecular weight of 194.15. The molecule is stable at acidic pH (less than 5) and labile at pH greater than 7; hence temozolomide can be administered orally and intravenously. The prodrug, temozolomide, is rapidly hydrolyzed to the active 5-(3-methyltriazen-1-yl) imidazole-4-carboxamide (MTIC) at neutral and alkaline pH values, with hydrolysis taking place even faster at alkaline pH.

Temozolomide Capsules:

Each capsule for oral use contains either 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, or 250 mg of temozolomide.

The inactive ingredients for temozolomide capsules are as follows: mannitol, croscarmellose sodium, stearic acid, citric acid anhydrous, colloidal silicon dioxide, and sodium lauryl sulfate.

The body of the capsules is made of gelatin, and is opaque white. The cap is also made of gelatin, and the colors vary based on the dosage strength. The capsule body and cap are imprinted with pharmaceutical branding ink, which contains shellac glaze in ethanol, iron oxide black, n-butyl alcohol, propylene glycol, ethanol, methanol, FD&C Blue No. 2 Aluminum Lake, FD&C Red No. 40 Aluminum Lake, FD&C Blue No. 1 Aluminum Lake, and D&C Yellow No. 10 Aluminum Lake.

Temozolomide 5 *mg*: The olive cap contains gelatin, titanium dioxide, yellow iron oxide, black iron oxide, and FD&C Blue No.1

Temozolomide 20 mg: The orange cap contains gelatin, titanium dioxide, yellow iron oxide, and red iron oxide

Temozolomide 100 mg: The flesh cap contains gelatin, titanium dioxide, and FD&C Red No. 40.

Temozolomide 140 mg: The aqua blue cap contains gelatin, titanium dioxide, and FD&C Blue No.1.

Temozolomide 180 mg: The swedish orange cap contains gelatin, titanium dioxide, FD&C Red No. 40, and FD&C Blue No. 1.

Temozolomide 250 mg: The white cap contains gelatin and titanium dioxide.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Temozolomide is not directly active but undergoes rapid nonenzymatic conversion at physiologic pH to the reactive compound 5-(3-methyltriazen-1-yl)-imidazoIe-4-carboxamide (MTIC). The cytotoxicity of MTIC is thought to be primarily due to alkylation of DNA. Alkylation (methylation) occurs mainly at the O^6 and N^7 positions of guanine.

12.3 Pharmacokinetics

Absorption: Temozolomide is rapidly and completely absorbed after oral administration with a peak plasma concentration (C_{max}) achieved in a median T_{max} of 1 hour. Food reduces the rate and extent of temozolomide absorption. Mean peak plasma concentration and AUC decreased by 32% and 9%, respectively, and median T_{max} increased by 2-fold (from 1-2.25 hours) when temozolomide was administered after a modified high-fat breakfast.

A pharmacokinetic study comparing oral and intravenous temozolomide in 19 patients with primary CNS malignancies showed that 150 mg/m² temozolomide for injection administered over 90 minutes is bioequivalent to 150 mg/m² temozolomide oral capsules with respect to both C_{max} and AUC of temozolomide and MTIC. Following a single 90-minute intravenous infusion of 150 mg/m², the geometric mean C_{max} values for temozolomide and MTIC were 7.3 mcg/mL and 276 ng/mL, respectively. Following a single oral dose of 150 mg/m², the geometric mean C_{max} values for temozolomide and 282 ng/mL, respectively. Following a single 90-minute intravenous infusion of 150 mg/m², the geometric mean AUC were 7.5 mcg/mL and 282 ng/mL, respectively. Following a single 90-minute intravenous infusion of 150 mg/m², the geometric mean AUC values for temozolomide and MTIC were 24.6 mcg·hr/mL and 891 ng·hr/mL, respectively. Following a single oral dose of 150 mg/m², the geometric mean AUC values for temozolomide and MTIC were 23.4 mcg·hr/mL and 864 ng·hr/mL, respectively.

Distribution: Temozolomide has a mean apparent volume of distribution of 0.4 L/kg (%CV=13%). It is weakly bound to human plasma proteins; the mean percent bound of drug-related total radioactivity is 15%.

Metabolism and Elimination: Temozolomide is spontaneously hydrolyzed at physiologic pH to the active species, MTIC and to temozolomide acid metabolite. MTIC is further hydrolyzed to 5-amino-imidazole-4-carboxamide (AIC), which is known to be an intermediate in purine and nucleic acid biosynthesis, and to methylhydrazine, which is believed to be the active alkylating species. Cytochrome P450 enzymes play only a minor role in the metabolism of temozolomide and MTIC. Relative to the AUC of temozolomide, the exposure to MTIC and AIC is 2.4% and 23%, respectively.

Excretion: About 38% of the administered temozolomide total radioactive dose is recovered over 7 days: 37.7% in urine and 0.8% in feces. The majority of the recovery of radioactivity in urine is unchanged temozolomide (5.6%), AIC (12%), temozolomide acid metabolite (2.3%), and unidentified polar metabolite(s) (17%). Overall clearance of temozolomide is about 5.5 L/hr/m². Temozolomide is rapidly eliminated, with a mean elimination half-life of 1.8 hours, and exhibits linear kinetics over the therapeutic dosing range of 75 to 250 mg/m²/day.

Effect of Age: A population pharmacokinetic analysis indicated that age (range: 19-78 years) has no influence on the pharmacokinetics of temozolomide.

Effect of Gender: A population pharmacokinetic analysis indicated that women have an approximately 5% lower clearance (adjusted for body surface area) for temozolomide than men.

Effect of Race: The effect of race on the pharmacokinetics of temozolomide has not been studied.

Tobacco Use: A population pharmacokinetic analysis indicated that the oral clearance of temozolomide is similar in smokers and nonsmokers.

Effect of Renal Impairment: A population pharmacokinetic analysis indicated that creatinine clearance over the range of 36 to 130 mL/min/m² has no effect on the clearance of temozolomide after oral administration. The pharmacokinetics of temozolomide have not been studied in patients with severely impaired renal function (CLcr less than 36 mL/min/m²). Caution should be exercised when temozolomide is administered to patients with severe renal impairment [*see Use in Special Populations (8.6)*]. Temozolomide has not been studied in patients on dialysis.

Effect of Hepatic Impairment: A study showed that the pharmacokinetics of temozolomide in patients with mild-to-moderate hepatic impairment (Child-Pugh Class I - II) were similar to those observed in

patients with normal hepatic function. Caution should be exercised when temozolomide is administered to patients with severe hepatic impairment [see Use in Specific Populations (8.7)].

Effect of Other Drugs on Temozolomide Pharmacokinetics: In a multiple-dose study, administration of temozolomide capsules with ranitidine did not change the C_{max} or AUC values for temozolomide or MTIC.

A population analysis indicated that administration of valproic acid decreases the clearance of temozolomide by about 5% [see Drug Interactions (7.1)].

A population analysis did not demonstrate any influence of coadministered dexamethasone, prochlorperazine, phenytoin, carbamazepine, ondansetron, H₂-receptor antagonists, or phenobarbital on the clearance of orally administered temozolomide.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Temozolomide is carcinogenic in rats at doses less than the maximum recommended human dose. Temozolomide induced mammary carcinomas in both males and females at doses 0.13 to 0.63 times the maximum human dose (25-125 mg/m²) when administered orally on 5 consecutive days every 28 days for 6 cycles. Temozolomide also induced fibrosarcomas of the heart, eye, seminal vesicles, salivary glands, abdominal cavity, uterus, and prostate, carcinomas of the seminal vesicles, schwannomas of the heart, optic nerve, and harderian gland, and adenomas of the skin, lung, pituitary, and thyroid at doses 0.5 times the maximum daily dose. Mammary tumors were also induced following 3 cycles of temozolomide at the maximum recommended daily dose.

Temozolomide is a mutagen and a clastogen. In a reverse bacterial mutagenesis assay (Ames assay), temozolomide increased revertant frequency in the absence and presence of metabolic activation. Temozolomide was clastogenic in human lymphocytes in the presence and absence of metabolic activation.

Temozolomide impairs male fertility. Temozolomide caused syncytial cells/immature sperm formation at 0.25 and 0.63 times the maximum recommended human dose (50 and 125 mg/m²) in rats and dogs, respectively, and testicular atrophy in dogs at 0.63 times the maximum recommended human dose (125 mg/m²).

13.2 Animal Toxicology and/or Pharmacology

Toxicology studies in rats and dogs identified a low incidence of hemorrhage, degeneration, and necrosis of the retina at temozolomide doses equal to or greater than 0.63 times the maximum recommended human dose (125 mg/m²). These changes were most commonly seen at doses where mortality was observed.

14 CLINICAL STUDIES


14.1 Newly Diagnosed Glioblastoma Multiforme

Five hundred and seventy-three patients were randomized to receive either temozolomide (TMZ)+Radiotherapy (RT) (n=287) or RT alone (n=286). Patients in the temozolomide+RT arm received concomitant temozolomide (75 mg/m²) once daily, starting the first day of RT until the last day of RT, for 42 days (with a maximum of 49 days). This was followed by 6 cycles of temozolomide alone (150 or 200 mg/m²) on Days 1 to 5 of every 28-day cycle, starting 4 weeks after the end of RT. Patients in the control arm received RT only. In both arms, focal radiation therapy was delivered as 60 Gy/30 fractions. Focal RT includes the tumor bed or resection site with a 2- to 3- cm margin. *Pneumocystis* pneumonia (PCP) prophylaxis was required during the TMZ+RT, regardless of lymphocyte count, and was to continue until recovery of lymphocyte count to less than or equal to Grade

At the time of disease progression, temozolomide was administered as salvage therapy in 161 patients of the 282 (57%) in the RT alone arm, and 62 patients of the 277 (22%) in the temozolomide+RT arm.

The addition of concomitant and maintenance temozolomide to radiotherapy in the treatment of patients with newly diagnosed GBM showed a statistically significant improvement in overall survival compared to radiotherapy alone (**Figure 1**). The hazard ratio (HR) for overall survival was 0.63 (95% CI for HR=0.52-0.75) with a log-rank *P*<0.0001 in favor of the temozolomide arm. The median survival was increased by 2.5 months in the temozolomide arm.

FIGURE 1: Kaplan-Meier Curves for Overall Survival (ITT Population)



14.2 Refractory Anaplastic Astrocytoma

A single-arm, multicenter study was conducted in 162 patients who had anaplastic astrocytoma at first relapse and who had a baseline Karnofsky performance status of 70 or greater. Patients had previously received radiation therapy and may also have previously received a nitrosourea with or without other chemotherapy. Fifty-four patients had disease progression on prior therapy with both a nitrosourea and procarbazine, and their malignancy was considered refractory to chemotherapy (refractory anaplastic astrocytoma population). Median age of this subgroup of 54 patients was 42 years (19-76). Sixty-five percent were male. Seventy-two percent of patients had a KPS of greater than 80. Sixty-three percent of patients had surgery other than a biopsy at the time of initial diagnosis. Of those patients undergoing resection, 73% underwent a subtotal resection and 27% underwent a gross total resection. Eighteen percent of patients had surgery at the time of first relapse. The median time from initial diagnosis to first relapse was 13.8 months (4.2-75.4).

Temozolomide capsules were given for the first 5 consecutive days of a 28-day cycle at a starting dose of 150 mg/m²/day. If the nadir and day of dosing (Day 29, Day 1 of next cycle) absolute neutrophil count was greater than or equal to 1.5×10^9 /L ($1500/\mu$ L) and the nadir and Day 29, Day 1 of next cycle platelet count was greater than or equal to 100×10^9 /L ($100,000/\mu$ L), the temozolomide dose was increased to 200 mg/m²/day for the first 5 consecutive days of a 28-day cycle.

In the refractory anaplastic astrocytoma population, the overall tumor response rate (CR+PR) was 22%

1.

(12/54 patients) and the complete response rate was 9% (5/54 patients). The median duration of all responses was 50 weeks (range: 16-114 weeks) and the median duration of complete responses was 64 weeks (range: 52-114 weeks). In this population, progression-free survival at 6 months was 45% (95% CI: 31%-58%) and progression-free survival at 12 months was 29% (95% CI: 16%-42%). Median progression-free survival was 4.4 months. Overall survival at 6 months was 74% (95% CI: 62%-86%) and 12-month overall survival was 65% (95% CI: 52%-78%). Median overall survival was 15.9 months.

15 REFERENCES

- 1. OSHA Technical Manual, TED 1-0.15A, Section VI: Chapter 2. Controlling Occupational Exposure to Hazardous Drugs. OSHA, 1999.
- 2. American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. *Am J Health-Syst Pharm*. 2006; 63:1172-1193.
- 3. NIOSH Alert: Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. 2004. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2004-165.[3]
- 4. Polovich, M., White, J. M., & Kelleher, L.O. (eds.) 2005. Chemotherapy and biotherapy guidelines and recommendations for practice (2nd. ed.) Pittsburgh, PA: Oncology.

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 Safe Handling and Disposal

Care should be exercised in the handling and preparation of temozolomide. Capsules should not be opened. If capsules are accidentally opened or damaged, rigorous precautions should be taken with the contents to avoid inhalation or contact with the skin or mucous membranes. The use of gloves and safety glasses is recommended to avoid exposure in case of breakage of the capsules. Procedures for proper handling and disposal of anticancer drugs should be considered {1-4}. Several guidelines on this subject have been published.

16.2 How Supplied

Temozolomide Capsules: Temozolomide capsules are supplied in amber glass bottles with child-resistant polypropylene caps containing the following capsule strengths:

Temozolomide Capsules 5 mg: have an olive opaque cap and white opaque body. They are imprinted with "Lannett" on the cap and "1777" over "5 mg" on the body and are supplied in: Bottles of 5 (NDC 0527-1777-55) Bottles of 14 (NDC 0527-1777-14)

Temozolomide Capsules 20 mg: have an orange opaque cap and white opaque body. They are imprinted with "Lannett" on the cap and "1778" over "20 mg" on the body and are supplied in: Bottles of 5 (NDC 0527-1778-55) Bottles of 14 (NDC 0527-1778-14)

Temozolomide Capsules 100 mg: have a flesh opaque cap and white opaque body. They are imprinted with "Lannett" on the cap and "1779" over "100 mg" on the body and are supplied in: Bottles of 5 (NDC 0527-1779-55) Bottles of 14 (NDC 0527-1779-14)

Temozolomide Capsules 140 mg: have an aqua blue opaque cap and white opaque body. They are imprinted with "Lannett" on the cap and "1780" over "140 mg" on the body and are supplied in: Bottles of 5 (NDC 0527-1780-55) Bottles of 14 (NDC 0527-1780-14)

Temozolomide Capsules 180 mg: have a swedish orange opaque cap and white opaque body. They are

imprinted with "Lannett" on the cap and "1781" over "180 mg" on the body and are supplied in: Bottles of 5 (NDC 0527-1781-55) Bottles of 14 (NDC 0527-1781-14)

Temozolomide Capsules 250 mg: have a white opaque cap and white opaque body. They are imprinted with "Lannett" on the cap and "1782" over "250 mg" on the body and are supplied in: Bottles of 5 (NDC 0527-1782-55)

16.3 Storage

Store temozolomide capsules at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].

17 PATIENT COUNSELING INFORMATION

See FDA-Approved Patient Labeling (Patient Information).

17.1 Information for the Patient

Physicians should discuss the following with their patients:

- Nausea and vomiting are the most frequently occurring adverse reactions. Nausea and vomiting are usually either self-limiting or readily controlled with standard antiemetic therapy.
- Capsules should not be opened. If capsules are accidentally opened or damaged, rigorous precautions should be taken with the capsule contents to avoid inhalation or contact with the skin or mucous membranes.
- The medication should be kept away from children and pets.

Manufactured by: Lannett Company, Inc. Philadelphia, PA 19136

Made in the USA

Rev. 12/2015, Revision 4

10-605

Patient Information

TEMOZOLOMIDE (tem-oh-ZOHL-oh-mide) Capsules

What is the most important information I should know about temozolomide?

• **Temozolomide may cause birth defects.** Male and female patients who take temozolomide capsules should use effective birth control. Female patients and female partners of male patients should avoid becoming pregnant while taking temozolomide.

See the section "What are the possible side effects of temozolomide?" for more information about side effects.

What is temozolomide?

Temozolomide is a prescription medicine used to treat adults with certain brain cancer tumors. Temozolomide blocks cell growth, especially cells that grow fast, such as cancer cells. Temozolomide may decrease the size of certain brain tumors in some patients.

It is not known if temozolomide is safe and effective in children.

Who should not take temozolomide?

Do not take temozolomide if you:

- have had an allergic reaction to dacarbazine (DTIC), another cancer medicine.
- have had a red itchy rash, or a severe allergic reaction, such as trouble breathing, swelling of the face, throat, or tongue, or severe skin reaction to temozolomide or any of the ingredients in temozolomide. If you are not sure, ask your doctor. See the end of the leaflet for a list of ingredients in temozolomide.

What should I tell my doctor before taking temozolomide?

Tell your doctor about all your medical conditions, including if you:

- are allergic to dacarbazine (DTIC) or have had a severe allergic reaction to temozolomide. See "Who should not take temozolomide?"
- have kidney problems
- have liver problems
- are pregnant. See "What is the most important information I should know about temozolomide?"
- are breast-feeding. It is not known whether temozolomide passes into breast milk. You and your doctor should decide if you will breast-feed or take temozolomide. You should not do both without talking with your doctor.

Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements. Especially tell your doctor if you take a medicine that contains valproic acid (Stavzor[®], Depakene[®]).

Know the medicines you take. Keep a list of them and show it to your doctor and pharmacist when you get a new medicine.

How should I take temozolomide?

Temozolomide may be taken by mouth as a capsule at home, or you may receive temozolomide by injection into a vein (intravenous). Your doctor will decide the best way for you to take temozolomide.

There are two common dosing schedules for taking temozolomide.

- Some people take temozolomide for 42 days in a row (possibly 49 days depending on side effects) with radiation treatment. This is one cycle of treatment. After this, you may have "maintenance" treatment. Your doctor may prescribe 6 more cycles of temozolomide. For each of these cycles, you take temozolomide one time each day for 5 days in a row and then you stop taking it for the next 23 days. This is a 28-day maintenance treatment cycle.
- Another way to take temozolomide is to take it one time each day for 5 days in a row only, and then you stop taking it for the next 23 days. This is one cycle of treatment (28 days). Your doctor will watch your progress on temozolomide and decide how long you should take it. You might take temozolomide until your tumor gets worse or for possibly up to 2 years.
- Your dose is based on your height and weight, and the number of treatment cycles will depend on how you respond to and tolerate this treatment.
- Your doctor may modify your schedule based on how you tolerate the treatment.
- If your doctor prescribes a treatment regimen that is different from the information in this leaflet, make sure you follow the specific instructions given to you by your doctor.

Temozolomide Capsules:

- Take temozolomide capsules exactly as prescribed.
- Temozolomide capsules come in different strengths. Each strength has a different color cap. Your doctor may prescribe more than one strength of temozolomide capsules for you, so it is important that you understand how to take your medicine the right way. Be sure that you understand exactly how many capsules you need to take on each day of your treatment, and what strengths to take. This may be different whenever you start a new cycle.
- Talk to your doctor before you take your dose if you are not sure how much to take. This will help to prevent taking too much temozolomide and decrease your chances of getting serious side effects.

- Take each day's dose of temozolomide capsules at one time, with a full glass of water.
- Swallow temozolomide capsules whole. Do not chew, open, or split the capsules.
- If temozolomide capsules are accidentally opened or damaged, be careful not to breathe in (inhale) the powder from the capsules or get the powder on your skin or mucous membranes (for example, in your nose or mouth). If contact with any of these areas happens, flush the area with water.
- If you vomit temozolomide capsules, do not take any more capsules. Wait and take your next planned dose.
- The medicine is used best by your body if you take it at the same time every day in relation to a meal.
- To lessen nausea, try to take temozolomide on an empty stomach or at bedtime. Your doctor may prescribe medicine to prevent or treat nausea, or other medicines to lessen side effects with temozolomide.
- See your doctor regularly to check your progress. Your doctor will check you for side effects that you might not notice.
- If you miss a dose of temozolomide, talk with your doctor for instructions about when to take your next dose of temozolomide.
- Call your doctor right away if you take more than the prescribed amount of temozolomide. It is important that you do not take more than the amount of temozolomide prescribed for you.

Temozolomide for Injection:

- You will receive temozolomide as an infusion directly into your vein. Your treatment will take about 90 minutes.
- Your doctor may prescribe medicine to prevent or treat nausea, or other medicines to relieve side effects with temozolomide.

What should I avoid while taking temozolomide?

• Female patients and female partners of male patients should avoid becoming pregnant while taking temozolomide. See "What is the most important information I should know about temozolomide?"

What are the possible side effects of temozolomide?

Temozolomide can cause serious side effects.

- See "What is the most important information I should know about temozolomide?"
- **Decreased blood cells.** Temozolomide affects cells that grow rapidly, including bone marrow cells. This can cause you to have a decrease in blood cells. Your doctor can monitor your blood for these effects.
 - White blood cells are needed to fight infections. Neutrophils are a type of white blood cell that help prevent bacterial infections. Decreased neutrophils can lead to serious infections that can lead to death. Other white blood cells called lymphocytes may also be decreased.
 - Platelets are blood cells needed for normal blood clotting. Low platelet counts can lead to bleeding. Tell your doctor about any unusual bruising or bleeding.

Your doctor will check your blood regularly while you are taking temozolomide to see if these side effects are happening. Your doctor may need to change the dose of temozolomide or when you get it depending on your blood cell counts. People who are age 70 or older and women may be more likely to have their blood cells affected.

- *Pneumocystis* pneumonia (PCP). PCP is an infection that people can get when their immune system is weak. Temozolomide decreases white blood cells, which makes your immune system weaker and can increase your risk of getting PCP. All patients taking temozolomide will be watched carefully by their doctor for this infection, especially patients who take steroids. Tell your doctor if you have any of the following signs and symptoms of PCP infection: shortness of breath and/or fever, chills, dry cough.
- **Secondary cancers.** Blood problems such as myelodysplastic syndrome and secondary cancers, such as a certain kind of leukemia, can happen in people who take temozolomide. Your doctor will

watch you for this.

- **Convulsions.** Convulsions may be severe or life-threatening in people who take temozolomide.
- Liver side effects have been reported, which very rarely included death.

Common side effects with temozolomide include:

- nausea and vomiting. Your doctor can prescribe medicines that may help reduce these symptoms.
- headache
- feeling tired
- loss of appetite
- hair loss
- constipation
- bruising
- rash
- paralysis on one side of the body
- diarrhea
- weakness
- fever
- dizziness
- coordination problems
- viral infection
- sleep problems
- memory loss
- pain, irritation, itching, warmth, swelling or redness at the site of infusion
- bruising or small red or purple spots under the skin

Tell your doctor about any side effect that bothers you or that does not go away.

These are not all the possible side effects with temozolomide. For more information, ask your doctor or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store temozolomide capsules?

- Store temozolomide capsules at 77°F (controlled room temperature). Storage at 59°F to 86°F (15°C to 30°C) is permitted occasionally.
- Keep temozolomide capsules out of the reach of children and pets.

General information about temozolomide.

Medicines are sometimes prescribed for purposes other than those listed in the Patient Information leaflet. Do not use temozolomide for a condition for which it was not prescribed. Do not give temozolomide to other people, even if they have the same symptoms that you have. It may harm them.

This leaflet summarizes the most important information about temozolomide. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about temozolomide that is written for health professionals.

For more information, contact Lannett Company, Inc. at 1-800-325-9994.

How are temozolomide capsules supplied?

Temozolomide capsules contain a white capsule body with a color cap and the colors vary based on the dosage strength. The capsules are available in six different strengths.

5 mg	Olive Cap
20 mg	Orange Cap
100 mg	Flesh Cap
140 mg	Aqua Blue Cap
180 mg	Swedish Orange Cap
250 mg	White Cap

What are the ingredients in temozolomide?

Temozolomide Capsules:

Active ingredient: temozolomide.

Inactive ingredients: mannitol, croscarmellose sodium, stearic acid, citric acid anhydrous, colloidal silicon dioxide, and sodium lauryl sulfate.

The body of the capsules is made of gelatin and is opaque white. The cap is also made of gelatin, and the colors vary based on the dosage strength. The capsule body and cap are imprinted with pharmaceutical branding ink, which contains shellac glaze in ethanol, iron oxide black, n-butyl alcohol, propylene glycol, ethanol, methanol, FD&C blue #2 aluminum lake, FD&C red # 40 aluminum lake, FD&C blue #1 aluminum lake, and D&C yellow # 10 aluminum lake.

Temozolomide 5 mg: The olive cap contains gelatin, titanium dioxide, yellow iron oxide, black iron oxide, and FD&C Blue #1.

Temozolomide 20 mg: The orange cap contains gelatin, titanium dioxide, yellow iron oxide, and red iron oxide.

Temozolomide 100 mg: The flesh cap contains gelatin, titanium dioxide, and FD&C Red #40.

Temozolomide 140 mg: The aqua blue cap contains gelatin, titanium dioxide, and FD&C Blue #1.

Temozolomide 180 mg: The swedish orange cap contains gelatin, titanium dioxide, FD&C Red #40, and FD&C Blue #1.

Temozolomide 250 mg: The white cap contains gelatin, and titanium dioxide.

Manufactured by: Lannett Company, Inc. Philadelphia, PA 19136

Made in the USA

Rev. 12/2015

10-614

The trademarks depicted herein are owned by their respective companies.

TEMOZOLOMIDE (tem-oh-ZOHL-oh-mide) Capsules

PHARMACIST:

Dispense enclosed Patient Package Insert to each patient.

PHARMACIST INFORMATION SHEET

IMPORTANT DISPENSING INFORMATION

For every patient, temozolomide must be dispensed in a separate vial or in original packaging making sure each container lists the strength per capsule and that patients take the appropriate number of capsules from each package or vial.

Please see the dispensing instructions below for more information.

What is temozolomide?

Temozolomide is an oral alkylating agent for the treatment of newly diagnosed glioblastoma multiforme and refractory anaplastic astrocytoma.


How is temozolomide dosed?

The daily dose of temozolomide capsules for a given patient is calculated by the physician, based on the patient's body surface area (BSA). The resulting dose is then rounded off to the nearest 5 mg. An example of the dosing may be as follows: the initial daily dose of temozolomide in milligrams is the BSA multiplied by mg/m²/day, (a patient with a BSA of 1.84 is 1.84 x 75 mg = 138, or 140 mg/day). The dose for subsequent cycles may be adjusted according to nadir neutrophil and platelet counts in the previous cycle and at the time of initiating the next cycle.

How might the dose of temozolomide be modified for Refractory Anaplastic Astrocytoma?

Dosage of temozolomide must be adjusted according to nadir neutrophil and platelet counts in the previous cycle and neutrophil and platelet counts at the time of initiating the next cycle. The initial dose is 150 mg/m² orally once daily for 5 consecutive days per 28-day treatment cycle. If both the nadir and day of dosing (Day 29, Day 1 of next cycle) absolute neutrophil counts (ANC) are greater than or equal to 1.5×10^{9} /L ($1500/\mu$ L) and both the nadir and Day 29, Day 1 of next cycle platelet counts are greater than or equal to 100×10^{9} /L ($100,000/\mu$ L), the temozolomide dose may be increased to 200 mg/m²/day for 5 consecutive days per 28-day treatment cycle. During treatment, a complete blood count should be obtained on Day 22 (21 days after the first dose) or within 48 hours of that day, and weekly until the ANC is above 1.5×10^{9} /L ($1500/\mu$ L) and the platelet count exceeds 100×10^{9} /L ($100,000/\mu$ L). The next cycle of temozolomide should not be started until the ANC and platelet count exceed these levels. If the ANC falls to less than 1×10^{9} /L ($1000/\mu$ L) or the platelet count is less than 50×10^{9} /L ($50,000/\mu$ L) during any cycle, the next cycle should be reduced by 50 mg/m², but not below 100 mg/m², the lowest recommended dose (see **Table 1** below).

TABLE 1: Dosing Modification Table forRefractory Anaplastic Astrocytoma



Based on lowest counts at either Day 22 or Day 29				
Ļ		ł		Ļ
ANC less than 1000/μL or platelets less than 50,000/μL		ANC 1000/μL – 1500/μL or platelets 50,000/μL – 100,000/μL		ANC greater than 1500/µL and platelets greater than 100,000/µL
Ļ		Ļ		Ļ
Postpone therapy until ANC greater than 1500/µL and platelets greater than 100,000/µL; reduce dose by 50 mg/m ² /d for subsequent cycle		Postpone therapy until ANC greater than 1500/µL and platelets greater than 100,000/µL; maintain initial dose		Increase dose to, or maintain dose at, 200 mg/m ² /d x 5d for subsequent cycle

What is the temozolomide capsules treatment regimen?

Temozolomide is given for 5 consecutive days on a 28-day cycle. Patients should continue taking temozolomide until their physician determines that their disease has progressed, up to 2 years, or until unacceptable side effects or toxicities occur. Physicians may alter the treatment regimen for a given patient.

Newly Diagnosed Concomitant Phase Treatment Schedule

Temozolomide is administered orally at 75 mg/m² daily for 42 days concomitant with focal radiotherapy (60 Gy administered in 30 fractions), followed by maintenance temozolomide for 6 cycles. No dose reductions are recommended; however, dose interruptions may occur based on patient tolerance. The temozolomide dose can be continued throughout the 42-day concomitant period up to 49 days if all of the following conditions are met: absolute neutrophil count greater than or equal to $1.5 \ge 10^9$ /L, platelet count greater than or equal to $100 \ge 10^{9}/L$, common toxicity criteria (CTC) nonhematological toxicity less than or equal to Grade 1 (except for alopecia, nausea and vomiting). During treatment a complete blood count should be obtained weekly. Temozolomide dosing should be interrupted or discontinued during concomitant phase according to the hematological and nonhematological toxicity criteria as noted in **Table 2**. *Pneumocystis carinii* pneumonia (PCP) prophylaxis is required during the concomitant administration of temozolomide and radiotherapy, and should be continued in patients who develop lymphocytopenia until recovery from lymphocytopenia (CTC grade less than or equal to 1).

TABLE 2: Temozolomide Dosing Interruption or Discontinuation During Concomitant Radiotherapy and Temozolomide

Toxicity	TMZ Interruption*	TMZ Discontinuation
Abaaluta	greater than or equal to	loss than

Absolute Neutrophil Count	0.5 and less than 1.5 x 10 ⁹ /L	1855 utan 0.5 x 10 ⁹ /L
Platelet Count	greater than or equal to 10 and less than 100 x 10 ⁹ /L	less than 10 x 10 ⁹ /L
CTC Non - hematological Toxicity (except for alopecia, nausea, vomiting)	CTC Grade 2	CTC Grade 3 or 4

*Treatment with concomitant TMZ could be continued when all of the following conditions were met: absolute neutrophil count greater than or equal to 1.5×10^9 /L; platelet count greater than or equal to 100 x 10^9 /L; CTC nonhematological toxicity less than or equal to Grade 1 (except for alopecia, nausea, vomiting). TMZ = temozolomide; CTC = Common Toxicity Criteria.

Maintenance Phase Treatment Schedule

Four weeks after completing the temozolomide + RT phase, temozolomide is administered for an additional 6 cycles of maintenance treatment. Dosage in Cycle 1 (maintenance) is 150 mg/m² once daily for 5 days followed by 23 days without treatment. At the start of Cycle 2, the dose is escalated to 200 mg/m², if the CTC nonhematologic toxicity for Cycle 1 is Grade less than or equal to 2 (except for alopecia, nausea and vomiting), absolute neutrophil count (ANC) is greater than or equal to 1.5×10^{9} /L, and the platelet count is greater than or equal to 100×10^{9} /L. If the dose was not escalated at Cycle 2, escalation should not be done in subsequent cycles. The dose remains at 200 mg/m² per day for the first 5 days of each subsequent cycle except if toxicity occurs.

During treatment a complete blood count should be obtained on Day 22 (21 days after the first dose) or within 48 hours of that day, and weekly until the ANC is above 1.5×10^9 /L ($1500/\mu$ L) and the platelet count exceeds 100×10^9 /L ($100,000/\mu$ L). The next cycle of temozolomide capsules should not be started until the ANC and platelet count exceed these levels. Dose reductions during the next cycle should be based on the lowest blood counts and worst nonhematologic toxicity during the previous cycle. Dose reductions or discontinuations during the maintenance phase should be applied according to **Tables 3** and **4**.

TABLE 3: Temozolomide Dose Levels for MaintenanceTreatment

Dose Level	Dose (mg/m ² /day)	Remarks
-1	100	Reduction for prior toxicity
0	150	Dose during Cycle 1
1	200	Dose during Cycles 2-6 in absence of toxicity

TABLE 4: Temozolomide Dose Reduction or DiscontinuationDuring Maintenance Treatment

Toxicity	Reduce TMZ by 1 Dose Level*	Discontinue TMZ
Absolute Neutrophil Count	less than 1 x 10 ⁹ /L	See footnote†
Platelet Count	less than 50 x 10 ⁹ /L	See footnote†
CTC Nonhematological		

*TMZ dose levels are listed in **Table 3**.

[†] TMZ is to be discontinued if dose reduction to less than 100 mg/m2 is required or if the same Grade 3 nonhematological toxicity (except for alopecia, nausea, vomiting) recurs after dose reduction.

TMZ = temozolomide; CTC = Common Toxicity Criteria.

How is temozolomide taken?

Patients should take each day's dose with a full glass of water at the same time each day. Taking the medication on an empty stomach or at bedtime may help ease nausea. If patients are also taking antinausea or other medications to relieve the side effects associated with temozolomide, they should be advised to take these medications 30 minutes before they take temozolomide. Temozolomide causes the rapid appearance of malignant tumors in rats. Patients **SHOULD NOT** open or split the capsules. If capsules are accidentally opened or damaged, rigorous precautions should be taken with the capsule contents to avoid inhalation or contact with the skin or mucous membranes. The medication should be kept away from children and pets. The temozolomide capsules should be swallowed whole and **NEVER CHEWED**.

What should the patient avoid during treatment with temozolomide?

There are no dietary restrictions for patients taking temozolomide. Temozolomide may affect testicular function, so male patients should exercise adequate birth control measures. Temozolomide may cause birth defects. Female patients should avoid becoming pregnant while receiving this drug. Women who are nursing prior to receiving temozolomide should discontinue nursing. It is not known whether temozolomide is excreted into breast milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants and tumorigenicity shown for temozolomide in animal studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of temozolomide to the mother.

What are the side effects of temozolomide?

Nausea and vomiting are the most common side effects associated with temozolomide. Noncumulative myelosuppression is the dose-limiting toxicity. Patients should be evaluated periodically by their physician to monitor blood counts.

Other commonly reported side effects reported by patients taking temozolomide are fatigue, constipation, alopecia, anorexia, and headache.

How is temozolomide supplied?

Temozolomide capsules are available in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths. The capsules contain a white capsule body with a color cap, and the colors vary based on the dosage strength.

Temozolomide Capsule Strength	Color
5 mg	Olive Cap
20 mg	Orange Cap
100 mg	Flesh Cap
140 mg	Aqua Blue Cap
180 mg	Swedish Orange Cap
250 mg	White Cap

The 5-mg, 20-mg, 100-mg, 140-mg, and 180-mg capsule strengths are available in 5-count and 14-count packages. The 250-mg capsule strength is available in a 5-count package.

How is temozolomide dispensed?

Each strength of temozolomide must be dispensed in its original package (one strength per one container). Follow the instructions below:

Based on the dose prescribed, determine the number of each strength of temozolomide capsules needed for the full 42- or 5-day cycle as prescribed by the physician. For example, in a 5-day cycle, 275 mg/day would be dispensed as five 250-mg capsules, five 20-mg capsules and five 5-mg capsules. Label each container with the appropriate number of capsules to be taken each day. Dispense to the patient, making sure each container lists the strength (mg) per capsule and that he or she understands to take the appropriate number of capsules of temozolomide from each package to equal the total daily dose prescribed by the physician.

How can temozolomide be ordered?

Temozolomide can be ordered from your wholesaler. It is important to understand if temozolomide is being used as part of a 42-day regimen or as part of a 5-day course. Remember to order enough temozolomide for the appropriate cycle.

For example:

- a 5-day course of 360 mg/day would require the following to be ordered: two 5-count packages of 180-mg capsules.
- a 42-day course of 140 mg/day would require the following to be ordered: three 14-count packages of 140-mg capsules.

For examples of other dosing regimens, please refer to the full **Prescribing Information (Table 6)**.

Temozolomide Product	NDC Number
Bottles:	
5-mg capsules (5 count)	0527-1777-55
5-mg capsules (14 count)	0527-1777-14
20-mg capsules (5 count)	0527-1778-55
20-mg capsules (14 count)	0527-1778-14
100-mg capsules (5 count)	0527-1779-55
100-mg capsules (14 count)	0527-1779-14
140-mg capsules (5 count)	0527-1780-55
140-mg capsules (14 count)	0527-1780-14
180-mg capsules (5 count)	0527-1781-55
180-mg capsules (14 count)	0527-1781-14
250-mg capsules (5 count)	0527-1782-55
Manufactured by	

Manufactured by: Lannett Company, Inc. Philadelphia, PA 19136 Made in the USA Rev. 12/2015 10-613

PRINCIPAL DISPLAY PANEL — 5 mg

NDC 0527-1777-55

TEMOZOLOMIDE CAPSULES

5 mg per capsule

For Oral Adminis tration

Rx Only

This package contains 5 Capsules

Lannett



PRINCIPAL DISPLAY PANEL - 20 mg

NDC 0527-1778-55

TEMOZOLOMIDE CAPSULES

20 mg per capsule

For Oral Administration

Rx Only

This package contains 5 Capsules

Lannett



PRINCIPAL DISPLAY PANEL - 100 mg

NDC 0527-1779-55

TEMOZOLOMIDE CAPSULES

100 mg per capsule

For Oral Administration

Rx Only

This package contains 5 Capsules

Lannett



PRINCIPAL DISPLAY PANEL — 140 mg NDC 0527-1780-55 TEMOZOLOMIDE CAPSULES

140 mg per capsule

For Oral Administration

Rx Only

This package contains 5 Capsules

Lannett



PRINCIPAL DISPLAY PANEL — 180 mg

NDC 0527-1781-55

TEMOZOLOMIDE CAPSULES

180 mg per capsule

For Oral Administration

Rx Only

This package contains 5 Capsules

Lannett



PRINCIPAL DISPLAY PANEL - 250 mg

NDC 0527-1782-55

TEMOZOLOMIDE CAPSULES

250 mg per capsule

For Oral Administration

Rx Only

This package contains

5 Capsules

Lannett



TEMOZOLOMIDE

temozolomide capsule

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0527-1777
Route of Administration	ORAL		

	Ingredient Name Basis of					
TEMOZOL	.OMIDE (UI	NII: YF1K15M17Y) (TEMOZOLOMIDE - UNII:YF1K15M1	7Y)	TEMOZOLO		Strength
	,					
Inactive	Ingredie	nts				
		Ingredient Name			St	rength
MANNITOI	L (UNII: 30)	WL53L36A)				
CROSCAR	MELLOSE	SODIUM (UNII: M28OL1HH48)				
STEARIC A	CID (UNII:	4ELV7Z65AP)				
ANHYDRO	US CITRIC	ACID (UNII: XF417D3PSL)				
SILICON D	IO XIDE (U	NII: ETJ7Z6XBU4)				
SODIUM L	AURYL SU	LFATE (UNII: 368GB5141J)				
GELATIN (UNII: 2G86	QN327L)				
TITANIUM	DIO XIDE (UNII: 15FIX9V2JP)				
FERRIC O	XIDE YELL	OW (UNII: EX438O2MRT)				
FERROSO	FERRIC OX	KIDE (UNII: XM0 M8 7F357)				
FD&C BLU	E NO. 1 (U	NII: H3R47K3TBD)				
SHELLAC ((UNII: 46 N1	07B71O)				
ALCOHOL	(UNII: 3K9	958V90M)				
BUTYL AL	COHOL (U	INII: 8 PJ6 1P6 TS3)				
PROPYLEN	NE GLYCO	L (UNII: 6DC9Q167V3)				
METHYL A	LCOHOL	(UNII: Y4S76JWI15)				
FD&C BLU	E NO. 2 (U	NII: L06K8R7DQK)				
FD&C RED	NO.40 (U	NII: WZB9127XOA)				
D&C YELL	OW NO. 10) (UNII: 35SW5USQ3G)				
	A O XIDE (U					
ALUMINUN						
ALUMINUN		ни. EMi2000333)				
Product	Characte			Score	no score	
Product Color	Characte	e ristics olive opaque cap) , WHITE (white opaque body)		Score Size	no score 16 mm	
Product Color Shape	Characte GREEN (e ristics olive opaque cap) , WHITE (white opaque body)				
Product Color Shape Flavor	Characte GREEN (e ristics olive opaque cap) , WHITE (white opaque body)		Size	16 mm	
Product	Characte GREEN (e ristics olive opaque cap) , WHITE (white opaque body)		Size	16 mm	
Product Color Shape Flavor	Characte GREEN (e ristics olive opaque cap) , WHITE (white opaque body)		Size	16 mm	
Product Color Shape Flavor Contains	Characte GREEN (CAPSUL	e ristics olive opaque cap) , WHITE (white opaque body)		Size	16 mm	
Product Color Shape Flavor Contains Packagin	Characte GREEN (CAPSUL	eristics (olive opaque cap) , WHITE (white opaque body) E	Marke	Size Imprint Code	16 mm Lannett;1	.777;5mg
Product Color Shape Flavor Contains Packagin # Item	Characte GREEN (CAPSUL	eristics (olive opaque cap) , WHITE (white opaque body) .E Package Description	Marke	Size	16 mm Lannett;1	.777;5mg
Product ⊂ Color Shape Flavor Contains Packagin # Item 1 NDC:052	Characte GREEN (CAPSUL CAPSUL	eristics (olive opaque cap) , WHITE (white opaque body) E	Marke	Size Imprint Code	16 mm Lannett;1	
Product Color Shape Flavor Contains Packagin # Item 1 NDC:052	Characte GREEN (CAPSUL CAPSUL	eristics (olive opaque cap) , WHITE (white opaque body) E Package Description 5 in 1 BOTTLE; Type 0: Not a Combination Product	Marke	Size Imprint Code	16 mm Lannett;1	.777;5mg
Product of Color Shape Flavor Contains Packagin # Item 1 NDC:052 2 NDC:052	C area (GREEN (CAPSUL CAPSUL CODE 7-1777-55 7-1777-14	eristics (olive opaque cap) , WHITE (white opaque body) E Package Description 5 in 1 BOTTLE; Type 0: Not a Combination Product	Marke	Size Imprint Code	16 mm Lannett;1	.777;5mg
Product of Color Shape Flavor Contains Packagin # 1 NDC:052 2 NDC:052	C area (GREEN (CAPSUL CAPSUL CODE 7-1777-55 7-1777-14	eristics (olive opaque cap), WHITE (white opaque body) (E) Package Description 5 in 1 BOTTLE; Type 0: Not a Combination Product 14 in 1 BOTTLE; Type 0: Not a Combination Product		Size Imprint Code	16 mm Lannett; 1	.777;5mg

TEMOZ	OLOM	IDE					
temozolomi	de capsu	le					
	1						
Product I	nformat	ion					
		1011	HUNAN DESCRIPTION DEUC	The C	1 (2)	NDC.0	507 1770
Product Ty			HUMAN PRESCRIPTION DRUG	Item Co	de (Source)	NDC:0	527-1778
Route of Ac	lministra	tion	ORAL				
Active Ing	gredient	Active Moi	ety				
			gredient Name		Basis of S	trength	Strength
TEMOZOLO	DMIDE (UI	NII: YF1K15M17Y) (TEMOZOLOMIDE - UNII:YF1K15M17Y)	TEMOZOLON	MIDE	20 mg
.	1.						
Inactive I	ngredie	nts					
			Ingredient Name			St	rength
MANNITOL	,						
		SODIUM (UNII:	M28OL1HH48)				
		4ELV7Z65AP)					
		ACID (UNII: XF4					
		NII: ETJ7Z6XBU					
		LFATE (UNII: 36	38GB5141J)				
GELATIN (U							
		UNII: 15FIX9V2J DW (UNII: EX43					
		JNII: 1K09F3G6					
SHELLAC (U	,						
ALCOHOL							
		TIDE (UNII: XMO)	M87F357)				
l		NII: 8 PJ6 1P6 TS3					
		L (UNII: 6DC9Q					
		UNII: Y4S76JWI					
FD&C BLUE	E NO. 2 (UI	NII: L06K8R7DQ	NK)				
FD&C RED	NO.40 (UI	NII: WZB9 127XO	A)				
FD&C BLUE	E NO.1 (UI	NII: H3R47K3TBI))				
D&C YELLO	W NO. 10) (UNII: 35SW5U	SQ3G)				
ALUMINUM	OXIDE (U	NII: LMI260693	3)				
Product C	Characte	ristics					
Color	ORANGE	(orange opaque	cap) , WHITE (white opaque body)	S	core	no score	
Shape	CAPSULE	2		S	ize	18 mm	
Flavor				Ŀ	mprint Code	Lannett;1	778;20mg
Contains							
Packaging	3						
# Item	Code	J	Package Description	Marketin	ng Start Date	Marketii	ng End Date
1 NDC:0527	-1778-55	5 in 1 BOTTLE;	Type 0: Not a Combination Product				

2 NDC:0527-	1778-14 14 in 1 B	OTTLE; Type 0: Not a Co	ombination Product				
Marketii	ng Informat	ion					
Marketing (-	lication Number or M	onograph Citation	Marketing	g Start Date	Marketii	ng End Date
ANDA		202750		03/23/2016	, otart Date	Mai Ke ui	ig Liiu Dutt
TEMOZO	OLOMIDE						
temozolomic	le capsule						
	nformation						
Product Typ	pe	HUMAN PRESCR	RIPTION DRUG	Item Code	(Source)	NDC:0	527-1779
Route of Ada	ministration	ORAL					
Active Ing	redient/Active	Moietv					
ricuve ing	realend/reave	Ingredient Name			Basis of S	trength	Strength
TEMOZOLO	MIDE (UNII) VE1K	15M17Y) (TEMOZOLOMI		1	TEMOZOLON	-	100 mg
I LIVIO ZO LO					TEMOZOLON		100 mg
Inactive In	ngredients						
Inactive In	ng re die nts	Ingredient	t Name			St	rength
	ng re die nts (UNII: 30WL53L36	_	t Name			St	rength
MANNITOL ((UNII: 30WL53L36	_	t Name			St	rength
MANNITOL (CROSCARMI	(UNII: 30WL53L36	A) (UNII: M28OL1HH48)	t Name			St	rength
MANNITOL (CROSCARMI STEARIC AC	(UNII: 30WL53L36 ELLOSE SODIUM	A) (UNII: M28OL1HH48) 5AP)	t Name			St	rength
MANNITOL (CROSCARMI STEARIC ACI ANHYDROUS	(UNII: 30WL53L36 ELLOSE SODIUM ID (UNII: 4ELV7Z6	A) (UNII: M28OL1HH48) 5AP) NII: XF417D3PSL)	t Name			St	rength
MANNITOL (CROSCARMI STEARIC AC ANHYDROUS SILICON DIO	(UNII: 30WL53L36 ELLOSE SODIUM ID (UNII: 4ELV7Z6 S CITRIC ACID (U	A) (UNII: M28OL1HH48) 5AP) NII: XF417D3PSL) Z6XBU4)	t Name			St	rength
MANNITOL (CROSCARMI STEARIC ACI ANHYDROUS SILICON DIO SODIUM LAU	(UNII: 30WL53L36 ELLOSE SODIUM ID (UNII: 4ELV7Z6 S CITRIC ACID (U) XIDE (UNII: ETJ7)	A) (UNII: M28OL1HH48) 5AP) NII: XF417D3PSL) Z6XBU4)	t Name			St	rength
MANNITOL (CROSCARME STEARIC AC ANHYDROUS SILICON DIO SODIUM LAU GELATIN (UP	(UNII: 30WL53L36 ELLOSE SODIUM ID (UNII: 4ELV7Z6 S CITRIC ACID (U D XIDE (UNII: ETJ7: URYL SULFATE (1	A) (UNII: M28OL1HH48) 5AP) NII: XF417D3PSL) Z6XBU4) UNII: 368GB5141J)	t Name			St	rength
MANNITOL (CROSCARMI STEARIC ACI ANHYDROUS SILICON DIO SODIUM LAU GELATIN (UP TITANIUM DI FD&C RED N	(UNII: 30WL53L36 ELLOSE SODIUM ID (UNII: 4ELV7Z6 S CITRIC ACID (U D XIDE (UNII: ETJ7: URYL SULFATE (NII: 2G86QN327L) IO XIDE (UNII: 15F IO . 40 (UNII: WZBS	A) (UNII: M28 O L 1HH48) 5AP) NII: XF417D3PS L) Z6 XBU4) JNII: 368 GB5141J) X9 V2JP)	t Name			St	rength
MANNITOL (CROSCARME STEARIC ACI ANHYDROUS SILICON DIO SODIUM LAU GELATIN (UN TITANIUM DI FD&C RED N SHELLAC (UN	(UNII: 30WL53L36 ELLOSE SODIUM ID (UNII: 4ELV7Z6 S CITRIC ACID (U) XIDE (UNII: ETJ72 URYL SULFATE (1 NII: 2G86QN327L) IOXIDE (UNII: 15F IO.40 (UNII: WZB9 NII: 46N107B710)	A) (UNII: M28 O L 1HH48) 5AP) NII: XF417D3PSL) Z6 XBU4) JNII: 368 GB5141J) X9 V2JP) 0 127XO A)	t Name			St	rength
MANNITOL (CROSCARME STEARIC ACI ANHYDROUS SILICON DIO SODIUM LAU GELATIN (UN TITANIUM DI FD&C RED N SHELLAC (UN	(UNII: 30WL53L36 ELLOSE SODIUM ID (UNII: 4ELV7Z6 S CITRIC ACID (U D XIDE (UNII: ETJ7: URYL SULFATE (NII: 2G86QN327L) IO XIDE (UNII: 15F IO . 40 (UNII: WZBS	A) (UNII: M28 O L 1HH48) 5AP) NII: XF417D3PSL) Z6 XBU4) JNII: 368 GB5141J) X9 V2JP) 0 127XO A)	t Name			St St	rength
MANNITOL (CROSCARMI STEARIC ACI ANHYDROUS SILICON DIO SODIUM LAU GELATIN (UP TITANIUM DI FD&C RED N SHELLAC (UI ALCOHOL (U	(UNII: 30WL53L36 ELLOSE SODIUM ID (UNII: 4ELV7Z6 S CITRIC ACID (U) XIDE (UNII: ETJ72 URYL SULFATE (1 NII: 2G86QN327L) IOXIDE (UNII: 15F IO.40 (UNII: WZB9 NII: 46N107B710)	A) (UNII: M28 O L 1HH48) 5AP) NII: XF417D3PSL) Z6 XBU4) UNII: 368 GB5141J) X9 V2JP) 0127XOA) A)	t Name			St St St	rength
MANNITOL (CROSCARMI STEARIC ACI ANHYDROUS SILICON DIO SODIUM LAU GELATIN (UP TITANIUM DI FD&C RED N SHELLAC (UI ALCOHOL (U FERROSOFE BUTYL ALCO	(UNII: 30WL53L36 ELLOSE SODIUM ID (UNII: 4ELV7Z6 S CITRIC ACID (U O XIDE (UNII: ETJ72 URYL SULFATE (1 NII: 2G86QN327L) IO XIDE (UNII: 15F IO XIDE (UNII: 15F IO XIDE (UNII: WZB5 NII: 46 N107B710) UNII: 3K9958 V90M ERRIC O XIDE (UN OHOL (UNII: 8PJ6	A) (UNII: M28 O L 1HH48) 5AP) NII: XF417D3PSL) Z6 XBU4) UNII: 368 GB5141J) (X9 V2JP) 0 127 XO A) (M) II: XM0 M8 7F357) 1P6 TS 3)	t Name			St St 3	rength
MANNITOL (CROSCARMI STEARIC ACI ANHYDROUS SILICON DIO SODIUM LAU GELATIN (UP TITANIUM DI FD&C RED N SHELLAC (UI ALCOHOL (U FERROSOFE BUTYL ALCO	(UNII: 30WL53L36 ELLOSE SODIUM ID (UNII: 4ELV7Z6 S CITRIC ACID (U D XIDE (UNII: ETJ7) URYL SULFATE (I NII: 2G86QN327L) IOXIDE (UNII: 15F IO.40 (UNII: WZBS NII: 46N107B710) UNII: 3K9958V90M ERRIC OXIDE (UN	A) (UNII: M28 O L 1HH48) 5AP) NII: XF417D3PSL) Z6 XBU4) UNII: 368 GB5141J) (X9 V2JP) 0 127 XO A) (M) II: XM0 M8 7F357) 1P6 TS 3)	t Name			St St 3	rength
MANNITOL (CROSCARME STEARIC ACT ANHYDROUS SILICON DIO SODIUM LAU GELATIN (UP TITANIUM DI FD&C RED N SHELLAC (UT ALCOHOL (UT FERROSOFE BUTYL ALCO PROPYLENE METHYL ALCO	(UNII: 30WL53L36 ELLOSE SODIUM ID (UNII: 4ELV7Z6 S CITRIC ACID (U) XIDE (UNII: ETJ72 URYL SULFATE (1 NII: 2G86QN327L) IOXIDE (UNII: 15F IO.40 (UNII: WZB9 NII: 46N107B710) UNII: 3K9958V90N ERRIC OXIDE (UN COHOL (UNII: 8PJ6 EGLYCOL (UNII: 44	A) (UNII: M28 O L 1HH48) 5AP) NII: XF417D3PSL) Z6 XBU4) Z0 XBU4) Z0 XBU4) (X9 V2JP) 0 127XO A) (X9 V2JP) 0 127XO A) (X9 V2JP) 10 C XM0 M8 7F357) 10 C Y C Y C Y C Y C Y C Y C Y C Y C Y C	t Name			St St 3 3 4 3 4 3 4 3 4 3 4 3 4 3 4 3 4 3 4	rength
MANNITOL (CROSCARMI STEARIC AC ANHYDROUS SILICON DIO SODIUM LAU GELATIN (UP TITANIUM D FD&C RED N SHELLAC (UI ALCOHOL (U FERROSOFE BUTYL ALCO PROPYLENE METHYL ALO FD&C BLUE	(UNII: 30 WL53L36 ELLOSE SODIUM ID (UNII: 4ELV7Z6 S CITRIC ACID (U D XIDE (UNII: ETJ7: URYL SULFATE (NII: 2G86QN327L) IO XIDE (UNII: 15F IO.40 (UNII: WZB9 NII: 46 N107B710) UNII: 3K9958 V90M ERRIC O XIDE (UNI COHOL (UNII: 8PJ6 COHOL (UNII: 8PJ6 COHOL (UNII: 245 NO.2 (UNII: L06K	A) (UNII: M28 O L 1HH48) 5AP) NII: XF417D3PSL) Z6 XBU4) UNII: 368 GB 5141J) (X9 V2JP) (X9 V2P) (X9 V2P) (X9 V2P) (X9 V2P) (X9 V2P)	t Name			St St 3 3 4 3 4 3 4 4 4 4 4 4 4 4 4 4 4 4 4	rength
MANNITOL (CROSCARME STEARIC AC) ANHYDROUS SILICON DIO SODIUM LAU GELATIN (UP TITANIUM D) FD&C RED N SHELLAC (U) ALCOHOL (U FERROSOFE BUTYL ALCO PROPYLENE METHYL ALCO FD&C BLUE	(UNII: 30WL53L36 ELLOSE SODIUM ID (UNII: 4ELV7Z6 S CITRIC ACID (U OXIDE (UNII: ETJ72) URYL SULFATE (U NII: 2G86QN327L) IOXIDE (UNII: 15F IO.40 (UNII: WZB5 NII: 46N107B710) UNII: 3K9958V90M ERRIC OXIDE (UN OHOL (UNII: 8PJ6 GLYCOL (UNII: 8PJ6 COHOL (UNII: 8PJ6 COHOL (UNII: 8PJ6 COHOL (UNII: 8PJ6 NO.2 (UNII: L06K NO.1 (UNII: H3R4)	A) (UNII: M28 O L 1HH48) 5AP) NII: XF417D3PS L) Z6 XBU4) Z6 XBU4) JUII: 368 GB5141J) Z6 XBU4) (X9 V2JP) 127XO A) (X9 V2JP) 127XO A) (X9 V2JP) 127XO A) (X9 V2JP) (X9 V2JP)	t Name			St St St St St St St St St St St St St S	rength
MANNITOL (CROSCARMI STEARIC ACI ANHYDROUS SILICON DIO SODIUM LAU GELATIN (UP TITANIUM DI FD&C RED N SHELLAC (UI ALCOHOL (U FERROSOFE BUTYL ALCO PROPYLENE METHYL ALCO FD&C BLUE FD&C BLUE	(UNII: 30WL53L36 ELLOSE SODIUM ID (UNII: 4ELV7Z6 S CITRIC ACID (U O XIDE (UNII: ETJ7: URYL SULFATE (NII: 2G86QN327L) IO XIDE (UNII: 15F O.40 (UNII: WZB9 NII: 46N107B710) UNII: 3K9958V90M ERRIC O XIDE (UN OHOL (UNII: 8PJ6 COHOL (UNII: 8) COHOL (UNII) (UNI	A) (UNII: M28 O L 1HH48) 5AP) NII: XF417D3PS L) Z6 XBU4) Z6 XBU4) UNII: 368 GB 5141J) Z7 XO A) (X9 V2JP) 127 XO A) (X9 V2JP) 127 XO A) (X9 V2JP) (X9 V2P	t Name			St St St St St St St St St St St St St S	rength
MANNITOL (CROSCARMI STEARIC ACI ANHYDROUS SILICON DIO SODIUM LAU GELATIN (UP TITANIUM DI FD&C RED N SHELLAC (UI ALCOHOL (U FERROSOFE BUTYL ALCO PROPYLENE METHYL ALCO FD&C BLUE FD&C BLUE	(UNII: 30WL53L36 ELLOSE SODIUM ID (UNII: 4ELV7Z6 S CITRIC ACID (U OXIDE (UNII: ETJ72) URYL SULFATE (U NII: 2G86QN327L) IOXIDE (UNII: 15F IO.40 (UNII: WZB5 NII: 46N107B710) UNII: 3K9958V90M ERRIC OXIDE (UN OHOL (UNII: 8PJ6 GLYCOL (UNII: 8PJ6 COHOL (UNII: 8PJ6 COHOL (UNII: 8PJ6 COHOL (UNII: 8PJ6 NO.2 (UNII: L06K NO.1 (UNII: H3R4)	A) (UNII: M28 O L 1HH48) 5AP) NII: XF417D3PS L) Z6 XBU4) Z6 XBU4) UNII: 368 GB 5141J) Z7 XO A) (X9 V2JP) 127 XO A) (X9 V2JP) 127 XO A) (X9 V2JP) (X9 V2P				St St 3 3 4 3 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	rength
MANNITOL (CROSCARMI STEARIC ACI ANHYDROUS SILICON DIO SODIUM LAU GELATIN (UP TITANIUM DI FD&C RED N SHELLAC (UI ALCOHOL (U FERROSOFE BUTYL ALCO PROPYLENE METHYL ALCO FD&C BLUE FD&C BLUE	(UNII: 30WL53L36 ELLOSE SODIUM ID (UNII: 4ELV7Z6 S CITRIC ACID (U O XIDE (UNII: ETJ7: URYL SULFATE (NII: 2G86QN327L) IO XIDE (UNII: 15F O.40 (UNII: WZB9 NII: 46N107B710) UNII: 3K9958V90M ERRIC O XIDE (UN OHOL (UNII: 8PJ6 COHOL (UNII: 8) COHOL (UNII) (UNI	A) (UNII: M28 O L 1HH48) 5AP) NII: XF417D3PS L) Z6 XBU4) Z6 XBU4) UNII: 368 GB 5141J) Z7 XO A) (X9 V2JP) 127 XO A) (X9 V2JP) 127 XO A) (X9 V2JP) (X9 V2P				St St St St St St St St St St St St St S	rength
MANNITOL (CROSCARMI STEARIC AC) ANHYDROUS SILICON DIO SODIUM LAU GELATIN (UP TITANIUM DI FD&C RED N SHELLAC (UI ALCOHOL (U FERROSOFE BUTYL ALCO PROPYLENE METHYL ALCO FD&C BLUE D&C YELLO ALUMINUM ((UNII: 30WL53L36 ELLOSE SODIUM ID (UNII: 4ELV7Z6 S CITRIC ACID (U O XIDE (UNII: ETJ7: URYL SULFATE (NII: 2G86QN327L) IO XIDE (UNII: 15F O.40 (UNII: WZB9 NII: 46N107B710) UNII: 3K9958V90M ERRIC O XIDE (UN OHOL (UNII: 8PJ6 COHOL (UNII: 8) COHOL (UNII) (UNI	A) (UNII: M28 O L 1HH48) 5AP) NII: XF417D3PS L) Z6 XBU4) Z6 XBU4) UNII: 368 GB 5141J) Z7 XO A) (X9 V2JP) 127 XO A) (X9 V2JP) 127 XO A) (X9 V2JP) (X9 V2P				St St St St St St St St St St St St St S	rength
MANNITOL (CROSCARMH STEARIC AC ANHYDROUS SILICON DIO SO DIUM LAU GELATIN (UP TITANIUM DI FD&C RED N SHELLAC (UI ALCOHOL (U FERROSOFE BUTYL ALCO PROPYLENE METHYL ALCO FD&C BLUE D&C YELLO ALUMINUM O	(UNII: 30WL53L36 ELLOSE SODIUM ID (UNII: 4ELV7Z6 S CITRIC ACID (U) XIDE (UNII: ETJ77 URYL SULFATE (I NII: 2G86QN327L) IOXIDE (UNII: 15F IO.40 (UNII: WZB9 NII: 46N107B710) UNII: 3K9958V90N ERRIC OXIDE (UN OHOL (UNII: 8PJ6 EGLYCOL (UNII: 8PJ6 COHOL (UNII: 8PJ6 EGLYCOL (UNII: 424 NO.2 (UNII: 106K NO.1 (UNII: H3R4' W NO.10 (UNII: 3 OXIDE (UNII: LMI2 haracteristics	A) (UNII: M28 O L 1HH48) 5AP) NII: XF417D3PS L) Z6 XBU4) Z6 XBU4) UNII: 368 GB 5141J) Z7 XO A) (X9 V2JP) 127 XO A) (X9 V2JP) 127 XO A) (X9 V2JP) (X9 V2P		Score		Image: State stat	rength

Flavor		Imprin	t Code La	nnett;1779;100mg
Contains				
Packaging				
# Item Code	Package Description	Marketing	Start Date I	Marketing End Date
1 NDC:0527-1779-55	5 in 1 BOTTLE; Type 0: Not a Combinatio	n Product		
2 NDC:0527-1779-14	14 in 1 BOTTLE; Type 0: Not a Combination	on Product		
Markating Inf	a v matia n			
Marketing Inf				
Marketing Categor			g Start Date	Marketing End Date
ANDA	ANDA202750	03/23/2016		
TEMOZOLON	IIDE			
temozolomide capsu	ıle			
Product Informa	tion			
Product Type	HUMAN PRESCRIPTION I	DRUG Item Code	(Source)	NDC:0527-1780
Route of Administra	tion ORAL			
Active Ingredien	t/Active Moiety			
	Ingredient Name		Basis of Str	rength Strength
TEMOZOLOMIDE (U	NII: YF1K15M17Y) (TEMOZOLOMIDE - UNI	EYF1K15M17Y)	TEMOZOLOM	-
			12010202000	110 mg
Inactive Ingredie	nto			
macuve mgreute				
	Ingredient Name			Strength
MANNITOL (UNII: 30				
	SODIUM (UNII: M28OL1HH48)			
STEARIC ACID (UNII:	,			
	ACID (UNII: XF417D3PSL)			
SILICON DIO XIDE (U				
	LFATE (UNII: 368GB5141J)			
GELATIN (UNII: 2G86				
TITANIUM DIO XIDE				
FD&C BLUE NO. 1 (U	,			
SHELLAC (UNII: 46N1				
ALCOHOL (UNII: 3K9				
	XIDE (UNII: XM0 M8 7F357)			
BUTYL ALCOHOL (U				
	L (UNII: 6DC9Q167V3)			
METHYL ALCOHOL				
FD&C BLUE NO. 2 (U	NII: L06K8R7DQK)			

FD&C RED NO. 40 (UNII: WZB9127XOA)

D&C YELI	D&C YELLOW NO.10 (UNII: 35SW5USQ3G)					
ALUMINU	ALUMINUM OXIDE (UNII: LMI2606933)					
Product	Characte	ristics				
Color	BLUE (ag	ua blue opaque cap) , WHITE (white opaque body)		Score	no score	
Shape	CAPSULE	2		Size	22mm	
Flavor				Imprint Code	Lannett;1780;140 mg	
Contains						
Packagi	ıg					
# Iten	ı Code	Package Description	Marke	eting Start Date	Marketing End Date	
1 NDC:052	7-1780-55	5 in 1 BOTTLE; Type 0: Not a Combination Product				
2 NDC:052	7-1780-14	14 in 1 BOTTLE; Type 0: Not a Combination Product				
Marke	Marketing Information					
Marketin	g Category	Application Number or Monograph Citation	Marl	keting Start Date	Marketing End Date	
ANDA		ANDA202750	03/23/	2016		

TEMOZOLOMIDE					
temozolomide capsule					
Product Information					
Product Type	HUMAN PRESCRIPTION DRUG	Item Code	(Source)	NDC:0	527-1781
Route of Administration	ORAL				
Active Ingredient/Active Moi	· ·				
	gredient Name		Basis of Stre	ength	Strength
In					
) (TEMOZOLOMIDE - UNII:YF1K15M17Y)		TEMOZOLOMID	ЭE	180 mg
	5		TEMOZOLOMID	ЭE	180 mg
TEMOZOLOMIDE (UNII: YF1K15M17Y	5		TEMOZOLOMID	θE	180 mg
	5		TEMOZOLOMID	DE	180 mg
TEMOZOLOMIDE (UNII: YF1K15M17Y	5		TEMOZOLOMID		180 mg rength
TEMOZOLOMIDE (UNII: YF1K15M17Y) (TEMOZOLOMIDE - UNII:YF1K15M17Y)		TEMOZOLOMID		
TEMOZOLOMIDE (UNII: YF1K15M17Y) (TEMOZOLOMIDE - UNII:YF1K15M17Y) Ingredient Name		TEMO ZO LO MID		
TEMOZOLOMIDE (UNII: YF1K15M17Y Inactive Ingredients MANNITOL (UNII: 30WL53L36A)) (TEMOZOLOMIDE - UNII:YF1K15M17Y) Ingredient Name		TEMO ZO LO MID		
TEMOZOLOMIDE (UNII: YF1K15M17Y Inactive Ingredients MANNITOL (UNII: 30WL53L36A) CROSCARMELLOSE SODIUM (UNII:) (TEMOZOLOMIDE - UNII:YF1K15M17Y) Ingredient Name M28OL1HH48)		TEMOZOLOMID		
TEMOZOLOMIDE (UNII: YF1K15M17Y Inactive Ingredients MANNITOL (UNII: 30WL53L36A) CROSCARMELLOSE SODIUM (UNII: STEARIC ACID (UNII: 4ELV7Z65AP)) (TEMOZOLOMIDE - UNII:YF1K15M17Y) Ingredient Name M28OL1HH48) 417D3PSL)		TEMOZOLOMID		
TEMOZOLOMIDE (UNII: YF1K15M17Y Inactive Ingredients MANNITOL (UNII: 30WL53L36A) CROSCARMELLOSE SODIUM (UNII: STEARIC ACID (UNII: 4ELV7Z65AP) ANHYDROUS CITRIC ACID (UNII: XF4) (TEMOZOLOMIDE - UNII:YF1K15M17Y) Ingredient Name M28OL1HH48) 417D3PSL) 4)		TEMOZOLOMID		
TEMOZOLOMIDE (UNII: YF1K15M17Y Inactive Ingredients MANNITOL (UNII: 30WL53L36A) CROSCARMELLOSE SODIUM (UNII: STEARIC ACID (UNII: 4ELV7Z65AP) ANHYDROUS CITRIC ACID (UNII: XF4 SILICON DIO XIDE (UNII: ETJ7Z6 XBU) (TEMOZOLOMIDE - UNII:YF1K15M17Y) Ingredient Name M28OL1HH48) 417D3PSL) 4)		TEMOZOLOMID		
TEMOZOLOMIDE (UNII: YF1K15M17Y Inactive Ingredients MANNITOL (UNII: 30WL53L36A) CROSCARMELLOSE SODIUM (UNII: STEARIC ACID (UNII: 4ELV7Z65AP) ANHYDROUS CITRIC ACID (UNII: XF4 SILICON DIO XIDE (UNII: ETJ7Z6XBU SODIUM LAURYL SULFATE (UNII: 36) (TEMOZOLOMIDE - UNII:YF1K15M17Y) Ingredient Name M28OL1HH48) 417D3PSL) 4) 68GB5141J)		TEMOZOLOMID		

FD&C BLU	E NO. 1 (U	NII: H3R47K3TBI	0)				
SHELLAC (UNII: 46N107B710)							
ALCOHOL		,					
		KIDE (UNII: XM0)	M87F357)				
		NII: 8 PJ6 1P6 TS3					
PROPYLEN	NE GLYCO	L (UNII: 6DC9Q	167V3)				
METHYL A	LCOHOL	(UNII: Y4S76JWI	15)				
FD&C BLU	E NO. 2 (U	NII: L06K8R7DQ	PK)				
D&C YELL	OW NO. 10) (UNII: 35SW5U	SQ3G)				
ALUMINUM	I O XIDE (U	JNII: LMI260693	3)				
Product	Characte	eristics					
Color	ORANGE	(swedish orange	opaque cap) , WHITE (white opaque body	y)	Score	no score	
Shape	CAPSULE				Size	22mm	
Flavor					Imprint Code	Lannett;1	781;180mg
Contains							
Packagin	•						
# Item	Code	I	Package Description	Marketin	g Start Date	Marketin	g End Date
1 NDC:052	7-1781-55	5 in 1 BOTTLE;	Type 0: Not a Combination Product				
2 NDC:052	7-1781-14	14 in 1 BOTTLE	; Type 0: Not a Combination Product				
Market	ing Inf	ormation					
	•		on Number or Monograph Citation	Marketi	ng Start Date	Marketin	ng End Date
Market Marketing ANDA	•		on Number or Monograph Citation	Marketi 03/23/2016	ng Start Date	Marketin	ng End Date
Marketing	•	y Applicatio				Marketin	ng End Date
Marketing	•	y Applicatio				Marketin	ıg End Date
Marketing ANDA	g Category	y Application				Marketir	ng End Date
Marketing ANDA TEMOZ	g Category	y Application				Marketin	ıg End Date
Marketing ANDA	g Category	y Application				Marketin	ng End Date
Marketing ANDA TEMOZ temozolom	g Category ZOLON nide capsu	y Application ANDA202750				Marketin	ıg End Date
Marketing ANDA TEMOZ temozolom Product	g Category ZOLON hide capsu	y Application ANDA202750		03/23/2016			
Marketing ANDA TEMOZ temozolom Product Product T	g Category ZOLON hide capsu Informat	y Application ANDA202750	HUMAN PRESCRIPTION DRUG	03/23/2016			1g End Date 527-1782
Marketing ANDA TEMOZ temozolom Product	g Category ZOLON hide capsu Informat	y Application ANDA202750		03/23/2016			
Marketing ANDA TEMOZ temozolom Product Product T	g Category ZOLON hide capsu Informat	y Application ANDA202750	HUMAN PRESCRIPTION DRUG	03/23/2016			
Marketing ANDA TEMOZ temozolom Product Product T Route of A	g Category 2OLOM nide capsu Informat ype .dministra	y Application ANDA202750	HUMAN PRESCRIPTION DRUG ORAL	03/23/2016			
Marketing ANDA TEMOZ temozolom Product Product T Route of A	g Category 2OLOM nide capsu Informat ype .dministra	y Application ANDA202750	HUMAN PRESCRIPTION DRUG ORAL	03/23/2016		NDC:0	
Marketing ANDA TEMOZ temozolom Product Product T Route of A Active In	g Category COLOM nide capsu Informat ype .dministra	y Application ANDA202750 IIDE ile tion tion t/Active Moie	HUMAN PRESCRIPTION DRUG ORAL	03/23/2016	e (Source)	NDC:0	527-1782
Marketing ANDA TEMOZ temozolom Product Product T Route of A Active In	g Category COLOM nide capsu Informat ype .dministra	y Application ANDA202750 IIDE ile tion tion t/Active Moie	HUMAN PRESCRIPTION DRUG ORAL ety gredient Name	03/23/2016	e (Source) Basis of St	NDC:0	527-1782 Strength

Inactive Ingredients

Ingredient NameStrengthMANNITOL (UNII: 30WL53L36A)CROSCARMELLOSE SODIUM (UNII: M280L1HH48)

	(UNII: 4ELV7Z65A	P)			
ANHYDRO US C	ITRIC ACID (UNI	: XF417D3PSL)			
SILICON DIO X	IDE (UNII: ETJ7Z6	XBU4)			
SODIUM LAUR	YL SULFATE (UN	II: 368GB5141J)			
GELATIN (UNII	2G86QN327L)				
TITANIUM DIO	XIDE (UNII: 15FIX	V2JP)			
SHELLAC (UNI	:46N107B71O)				
ALCOHOL (UN	II: 3K9958V90M)				
FERROSOFERI	RIC OXIDE (UNII:	XM0 M8 7F357)			
BUTYL ALCOR	IO L (UNII: 8 PJ6 1P	5TS3)			
PROPYLENE G	LYCOL (UNII: 6D	C9Q167V3)			
METHYL ALCO	HOL (UNII: Y4S76	5 JWI15)			
FD&C BLUE NO).2 (UNII: L06K8F	R7DQK)			
FD&C RED NO.	40 (UNII: WZB912	7XOA)			
FD&C BLUE NO	D. 1 (UNII: H3R47K	3TBD)			
D&C YELLOW	NO. 10 (UNII: 355	W5USQ3G)			
ALUMINUM OX	IDE (UNII: LMI260	06933)			
Product Cha			0		
		e cap and white opaque body)	Sco		no score
F -	APSULE		Siz		22mm
Flavor			Imp	rint Code	Lannett;1782;250mg
Contains					
Contains					
Contains					
Packaging	de	Package Description	Marke	ting Start Date	• Marketing End Date
Packaging # Item Co		Package Description TLE; Type 0: Not a Combination Product	Marke	ting Start Date	• Marketing End Date
Packaging # Item Co			Marke	ting Start Date	• Marketing End Date
Packaging # Item Co			Marke	ting Start Date	• Marketing End Date
Packaging # Item Co 1 NDC:0527-178		TLE; Type 0: Not a Combination Product	Marke	ting Start Date	e Marketing End Date
Packaging # Item Co 1 NDC:0527-178	32-55 5 in 1 BOT	TLE; Type 0: Not a Combination Product		ting Start Date	
Packaging # Item Co 1 NDC:0527-178 Marketing	32-55 5 in 1 BOT	TLE; Type 0: Not a Combination Product N cation Number or Monograph Citation		ceting Start Date	

Labeler - Lannett Company, Inc. (002277481)

Establishment

Name	Address	ID/FEI	Business Operations
Lannett Company, Inc.		002277481	MANUFACTURE(0527-1777, 0527-1778, 0527-1779, 0527-1780, 0527-1781, 0527-1782)

Establishment

Name	Address	ID/FEI	Business Operations
Lannett Company, Inc.		829757603	ANALYSIS(0527-1777, 0527-1778, 0527-1779, 0527-1780, 0527-1781, 0527-1782), LABEL(0527- 1777, 0527-1778, 0527-1779, 0527-1780, 0527-1781, 0527-1782), MANUFACTURE(0527-1777, 0527- 1778, 0527-1779, 0527-1780, 0527-1781, 0527-1782), PACK(0527-1777, 0527-1778, 0527-1779, 0527-1780, 0527-1781, 0527-1782)

Revised: 4/2016